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COMPARISON OF DIF  OF PLUCKED HAIR AND SKIN FOR EVALUATION OF 
IMMUNOLOGICAL REMISSION IN PEMPHIGUS 
 
INTRODUCTION: 
Demonstration of intercellular deposition of IgG on the cell surface of keratinocytes by 
DIF of perilesional skin is the gold standard in diagnosis of  Pemphigus. DIF of plucked 
hair demonstrating intercellular space deposition of IgG in the outer root sheath(ORS) 
has shown to be a useful test with sensitivity ranging from 85-100%.  
 
AIM AND OBJECTIVE: 
 
Our objective was to compare DIF of plucked hair and skin for evaluation of 
immunological remission in patients with clinical remission. 
 
METHODOLOGY: 
 
30 patients of Pemphigus who showed positive DIF  of skin and hair at baseline were 
included in the study. DIF of skin and hair was repeated after 6 months or more of 
clinical remission (with no new /non healing lesions). Presence of intercellular space 
deposits of IgG and or C3 in skin and ORS of hair was considered positive. 
 
RESULTS: 
 
Out of 30 patients  
 Both skin and hair DIF was positive in 8,  
 Both hair and skin DIF was negative in 14,  
 DIF skin was positive and hair was negative in 2 patients and 
 DIF of hair was positive and skin negative in 6 patients. 
 
CONCLUSION: 
 
DIF of hair and skin correlated with each other in 22 (73.3%) patients and sensitivity of 
hair DIF was 70% and specifity was 80%. The sensitivity was not high enough to suggest 
that it could replace the use of skin or mucosal DIF  for assessment of immunological 
remission. However, in 6 (20%) patients the positivity of hair DIF in spite of skin being 
negative cannot be disregarded. Hence, this could be a recommended additional 
procedure to assess immunological remission as it is non-invasive and cost effective. 
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INTRODUCTION 
 Pemphigus is a chronic autoimmune blistering disorder of the skin and 
mucosa. The word pemphigus, is derived from the greek word “pemphix” 
meaning  a bubble or blister. It is characterized by  the development of flaccid 
intraepidermal bullae, erosions and ulcerations over the skin and/ or mucosa 
with  antibodies directed against desmogleins 1 and 3.1  Direct 
immunofluorescence of peri-lesional skin or mucosa showing intercellular 
space (ICS) deposition of IgG  and/or C3 is considered as the gold standard in 
the diagnosis of pemphigus.    
 Systemic steroids alone or in combination with other 
immunosuppressives are the mainstay of treatment and long-term 
administration of the same is associated with significant adverse effects, 
morbidity and mortality.  It has been shown that upto 77% of deaths in 
pemphigus was related to high dose corticosteroids.2 
 
 Therefore, a system is required to monitor disease activity so as to lower 
the dosage of the drugs and eventually withdraw treatment. The main aim of 
treatment in pemphigus is to attain clinical and immunological remission. 
Hence, the most challenging decision we face in the management of this 
disease is the decision regarding when to stop the treatment. Various methods 
for assessment of immunological remission include: direct 
immunofluorescence, indirect immunofluorescence and anti-desmoglein 
ELISA titres, of which IIF is commonly used.3-8 However, indirect 
immunofluorescence titres do not always correlate with the disease activity.9-12 
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 It has been shown that negative direct immunofluorescence  of skin or 
mucosa is considered as a good indicator of immunological remission.13-16 But, 
it is an invasive and expensive procedure and the patient may not be willing for 
the same.  
 Recently, pemphigus-specific immunofluorescence pattern has been 
demonstrated in the outer root sheath of hair follicles which is structurally 
similar to the epidermal keratinocytes, with a sensitivity ranging from 85-
100%.17-20 
  Hence, DIF of hair may be an ideal substrate for assessment of 
immunological remission as it is a simple, non- invasive and a cost effective 
procedure.  
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AIM 
 
 Comparison of  direct Immunofluorescence of plucked hair and skin for 
evaluation of immunological remission in pemphigus. 
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REVIEW OF LITERATURE 
 
 
HISTORY 
  
 
 Pemphigus was probably first described by McBride in the year 1777 
and Wichmann in 1791. Wichmann applied the term “pemphigus” to his 
patients who had flaccid bullae and painful oral ulcers.21 
 
 In 1844 -  Cazenave first described pemphigus foliaceus as a  
superficial, rapidly spreading form of pemphigus.22,23  
 
           In 1868, Ferdinand von Hebra stated  that pemphigus was a chronic 
disease and was the first to coin the term pemphigus vulgaris.21.24 
 
  In 1886, Neumann described a disease with “warty granulations” as 
pemphigus vegetans.21,22,24 
 
In 1881- disruption of epidermal cells in patients with pemphigus, was 
first described by Auspitz. 25,26 
 
            In 1926, Senear and Usher described pemphigus erythematosus.  
 
In 1943, Civatte delineated acantholysis as histopathologic hallmark in 
pemphigus.  He described acantholysis and intraepithelial bulla formation in 
pemphigus vulgaris, pemphigus foliaceus and pemphigus vegetans. These 
findings  distinguished  pemphigus from other blistering disorder of the skin.28 
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In 1953, Walter Levers distinguished pemphigus vulgaris and 
pemphigoid bullosus, by both clinical and histological parameters. He 
described  pemphigus vulgaris as a life-threatening disease, characterized by 
intra-epidermal blisters and acantholysis with usually a lethal outcome,.29 
 
 In 1964, Beutner and Jordon using indirect immunofluorescence 
demonstrated auto-antibodies on the cell surface of keratinocytes.30 
 
 In 1976- Schiltz and Michel demonstrated that autoantibodies in 
pemphigus cause the blister formation by human skin organ culture.31 
 
 In 1982, Anhalt et al demonstrated the same using passive transfer of 
antibodies to neonatal mice.32 
 
 In 1980s, pemphigus target antigens were identified by 
immunoprecipitation and immunoblotting methods.33,34 
 
 In the early 1990s, isolation of cDNA for pemphigus antigens revealed 
the desmogleins as the target antigens in pemphigus.35,36 
 
 
EPIDEMIOLOGY 
 
IN INDIA 
 
The incidence of pemphigus in India, among the out-patient attendees 
ranges  from 0.09%- 1.8%. 37,38 
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Study conducted in Thrissur Kerala, has shown the incidence of 
pemphigus to be 4.4 per million population/year.39 
 
Pemphigus Vulgaris was the most commonest accounting for about           
75-96% of the total Pemphigus patients.38,40 
 
A review article by Sehgal et al, showed that P.V was the most 
commonest followed pemphigus foliaceous, pemphigus erythematosus, 
pemphigus Vegetans in decreasing order of frequency.40 
 
Incidence of pemphigus is more common in Ashkenazi jews, Japanese 
and Indians.40,41 
 
 
WORLD WIDE 
 
 
 P.V prevalence ranges from 0.18 to 6.96 case per million population.42,43 
 
 A study showed that, the proportion of PV and PF was almost equal in 
patients from UK, while PV was the predominant type in Indian 
patients.44  
 In Tunisia- incidence is about 2.5 cases per million population/ year.45 
 
 In france- incidence is 1.3 cases per million population/year. 45 
 
 In finland- prevalence is  0.76 cases per million population.46 
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AGE 
 
In India, P.V seems to affect the younger age group, in the 3rd to 4th 
decade.37,40,47  This is in contrast to the western countries, where the common  
age of onset was 50-60 years.48 
  
 
GENDER 
 
 
Both males and female are equally affected. Although,  in few studies 
the gender predisposition has contrasting results.49 
 
RACE 
 
More common in Ashkenazi Jews and Mediterranean population.48 
 
 
 
GENETIC FACTORS 
 
 
Pemphigus belongs to a group of polygenic disorder.  
 
 
 The higher incidence of pemphigus vulgaris and the earlier age of onset 
of pemphigus seen in India have been linked to higher frequency of  
DSG3*TCCCC halotype in Indian patients.50 
 
HLA DRB1 *0402, 1401/04, HLA DQB1 * 0503 has been associated   
with increased susceptibility to PV, HLA DRB1 *04 associated with P.F (both 
sporadic and endemic form) and HLA DRB1 *0102, 0404 & 1402/06 
associated with endemic P.F.51-54 
 
8 
 
These evidence suggests that genetic factors are probably involved in the 
disease. 
An inherited predisposition is further supported by the following evidence: 
 
a. Difference in clinical profile of Pemphigus between different ethnic 
groups. 
b. Ashkenazi Jews are more commonly affected. 
 
c. PV occurring in South African Indians is similar to that occurring in 
their origin country.55 
d. 40-60% of 1st degree relatives of patients with P.V have shown 
circulating anti- desmoglein antibodies. 52,56  
e. The first-degree relatives of patients with pemphigus have an increased 
prevalence of auto-immune diseases.57 
f. Familial cases have been reported.58 
 
 
 
DISEASE ASSOCIATIONS 
 
Pemphigus has been associated with SLE, Myasthenia gravis, thymoma,  
lymphoproliferative diseases.59,60  
  
 Herpes simplex, EB virus, HHV 6 and 8 DNA have been detected in 
skin or  mononuclear cells of  pemphigus patients 61,62 and there are reports of 
patients with pemphigus and coexisting HIV infection.63
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  A study on Iranian PV patients showed a positive correlation with oral 
contraceptive use and pesticide exposure.64 
 
PATHOGENESIS 
 
The hallmark of pemphigus is the presence of IgG auto-antibodies 
directed against desmoglein 3 and/or 1. These antibodies play an important role 
in the loss of keratinocyte cell to cell adhesion and subsequent blister 
formation. 
 
DESMOSOMES AND DESMOGLEINS 
 
Adhesion of keratinocytes is mainly by the cadherins. These cadherins 
are calcium dependant transmembrane glycoproteins, localized in two adhesion 
junctions, the desmosomes and the adherens junctions. The Desmosomes are 
the electron-dense structures that are responsible for anchoring the intermediate 
filament within the keratinocytes to the plasma membrane and adjacent cells.65   
. 
 The  components of desmosomes are: the desmosomal cadherins 
(desmogleins and desmocollins), the armadillo  proteins (plakoglobin, 
plakophilin) and the plakins (desmoplakin, etc) of which desmogleins and 
desmocollins are the major components.66 
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COMPONENTS OF A DESMOSOME65 
 
Figure - 1 
dp- desmoplakin, Dsg- Desmoglein, pkp- Desmoplakin, dsc- Desmocollins, 
kf- keratin intermediate filaments, dg- Desmoglea, odp- Outer dense plaque, 
idp- Inner Dense Plaque, pm- Plasma Membrane, dm- Dense midline. 
 
 
 
 In the desmosomes, cadherins are the transmembrane components and 
plakoglobin, plakophilin, and desmoplakin are the cytoplasmic components. 66 
 
 The desmoplakins form the major part of the inner dense plaque and its 
carboxy terminus binds to the keratin intermediate filaments and the amino 
terminus binds to the plakoglobin. Various domains in the plakoglobins in turn 
binds to the desmogleins and the desmocollins. The plakophilins binds to 
various desmosomal components and help in clustering and stabilizing them.67 
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STRUCTURE OF DESMOGLEINS:66 
 
 
 
 
 
Figure - 2 
 
 
 All the cadherins contain repeated amino acid sequences, called 
cadherin repeats, which have calcium-binding motifs in their extracellular 
domains. Like the classic cadherins, desmogleins have four cadherin repeats in 
their extracellular domain, but with an extra carboxy-terminal domain with 
repeats of 29 ± 1 aminoacid residues  in their intracellular domain. 66 
 
DISTRIBUTION OF DESMOGLEINS IN THE SKIN. 
 
 Desmogleins have four isoforms, Dsg 1 to 4.  Desmoglein 1 and 3 is 
expressed in the stratified squamous epithelia, while Dsg2 is expressed in all 
desmosome possessing tissues, predominantly in simple epithelia. Desmoglein 
4 is found in hair follicles and the granular layer.66 
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The expression of desmogleins in the skin varies based on the 
differentiation and also its expression pattern in mucosa differs from that in the 
skin. Desmoglein-3 expression is restricted to the basal and suprabasal layers of 
the epidermis, whereas desmoglein-1 is present in the entire thickness of the 
epidermis but more in the  differentiated cells, i.e, in the upper layers.68-70 
 
In mucosae, dsg-1 expression is weak, whereas, dsg-3 is strongly 
expressed throughout.69 
  
Pemphigus IgG antibody binds to the extracellular domain on the 
amino-terminal region of dsg-3.  Where it has a direct effect on the function of 
the desmogleins.72,73 
 
 The pathogenicity of Dsg antibodies depends on their titre and subclass. 
In patients with active disease, both IgG1 and IgG4 subclass antibodies are 
present, but the IgG4 is more specific and pathogeneic.74,75 
 
The pathogenicity of desmoglein antibodies is supported by,  
 
a) Studies showing a correlation between titre of antibody in patient’s 
serum and the disease activity. 76-78 
 
b)  transient bullae in the newborn may be caused by Transplacental 
transfer of maternal PV antibodies.79 
 
c) PV  IgG antibodies causes suprabasal  acantholysis in neonatal mouse 
model.80  
 
d) Prior absorption of antibodies of the pemphigus vulgaris prevents blister 
formation.81  
 
e) desmoglein-3 antibodies can induce acantholysis can in mice which can 
be enhanced by adding desmoglein-1 antibodies.82 
13 
 
DISTRIBUTION OF DESMOGLEINS IN THE HAIR 
 
Desmoglein 1 
 It’s expressed in the differentiated cells. In the inner root sheath and 
in the infundibulum of hair follicle its distribution is similar to that found in the 
epidermis.68 At the level of bulge its confined to the suprabasal layers and 
undetectable in the basal layer.68 Towards the base of the hair follicle dsg 1 
distribution gradually becomes confined to the inner most layers of the ORS 
and eventually disappears in the lowermost part of the hair follicle ORS.68 
Desmoglein 2 
 
 It’s highly expressed in the least differentiated cells such as the basal 
layers of the bulge region of hair follicle and bulb matrix.68   It’s also present in 
the basal cells of the ORS in the lower part of the hair follicle.68 
Desmoglein 3 
 
 Dsg 3 expression pattern correlated to the type of keratinisation. It is 
present in all the layers of outer root sheath, predominantly in the basal              
layers. 68   At the level of infundibulum its expressed predominantly in the basal 
layers.68   Its also expressed in the cyst walls in the areas of trichilemmal 
keratinisation, medulla of the hair shaft and in the suprabasal matrix and the 
precortical cells. 68   Dsg 3 also anchors the telogen hair to ORS of  the 
follicle.83 
Desmoglein 4 
 Dsg4 is expressed in the suprabasal epidermis and  the IRS , pre-cortex 
and the matrix.84 
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DISTRIBUTION OF DESMOGLEIN 1 & 3 IN THE HAIR 
FOLLICLE 
 
 
Figure - 3 
 
Table - 1 
DSG EXPRESSION IN HAIR FOLLICLE- SUMMARY68 
 
REGION DSG 1 DSG 2 DSG 3 
Basal cells of infundibulum +/- + ++ 
Infundibulum -suprabasal 
cells of  
+++ - + 
Isthmus - Suprabasal cells of 
ORS 
++++ + to - +++ to - 
Suprabasal cells of ORS from 
suprabulbar region to bulge.  
- To ++ ++ to - +++ to ++ 
Bulge region  - +++ + 
Basal cells of ORS below the 
bulge region 
- ++ to +++ +/- 
Precortical cells - + + 
Medulla + - +++ 
Inner Root Sheath +++ - - 
Matrix  - ++ +/- 
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DESMOGLEIN COMPENSATION THEORY85 
 
 
 
Figure - 4 
 
 The triangles represent the Desmoglein 1 and 3 distribution. 
 Green triangle- Dsg 1 & Red triangle- Dsg3. 
 A - skin and B - mucous membrane.  
 
A1- In pemphigus foliaceus antibodies are present only against dsg 1. 
Hence, blisters occur only in the superficial layers of the epidermis  as Dsg3 
functionally compensates for the impaired function of dsg 1 in the lower  
epidermis, 
 
A2- In mucosal dominant PV,  only anti-desmoglein 3 antibodies are 
present & hence, there’s  no or only limited bullae  in the skin as desmoglein 1 
compensates for the Dsg3 loss;  
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B2- However, in mucosal dominant PV erosions and bulla occur in the 
mucous membranes, as it has low levels of Desmoglein 1 and will not 
compensate for the Dsg 3 loss .  
 
A3, B3-When sera contain both anti-Dsg1 and anti-Dsg3 IgG, the 
function of both Dsgs is compromised and blisters occur in both the skin and 
mucous membranes. 
 
In neonatal skin, the situation is similar to that shown here for mucous 
membranes. 
 
Acantholysis is the basic patho- mechanism of pemphigus. However, the 
exact mechanism of disruption of adhesion between keratinocytes is not fully 
known.  
 
The following mechanisms have been proposed: 
 
1. STEARIC HINDRANCE 
Binding of the antibodies to the target antigen can cause disruption of 
it’s  adhesion function by stearic hindrance. 86 
 
2. BASAL CELL SHRINKAGE THEORY 
The PV antibodies induces phosphorylation of adhesion molecules and 
structural proteins leading to weakening of the intercellular junction and 
collapse of the cytoskeleton respectively.  This in-turn leads to cellular 
shrinkage and separation of the keratinocytes.87-89 
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3. APOPTOLYSIS HYPOTHESIS 
This theory links the suprabasal acantholysis and cell death pathway to  
basal cell shrinkage.90 
 
Binding of antibodies to keratinocyte 
Activation of signaling elements 
Elevation of intracellular calcium 
Activation of caspases 
Basal cell shrinkage causing acantholysis starts.( due to of cortical actin 
filaments reorganization and collapse and retraction of  tonofilaments, cleaved 
by caspases ) 
 
Acantholysis progresses due to Activated cell death enzymes causing  cleavage 
of  cellular proteins  leading to cell collapse, 
 
Desmosomes Tearing off from the cell membrane & thus stimulate production  
of secondary antibody. 
 
Rounding up and death of acantholytic cells ( in the lower compartment of 
epidermis  secondary to irreversible damage to nuclear and mitochondrial 
proteins). 
 
 
Thus, according to this theory same cell death enzymes, mediate both 
acantholysis and apoptosis of keratinocytes. 
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4. MULTIPLE HIT HYPOTHESIS 
 According to this hypothesis, apart from Dsg 1 and 3 antibodies other 
antibodies directed against desmosomal proteins like plakins, desmocollins  
and non desmosomal proteins like Acetylcholine α 9 receptors, phemphaxin, 
thyroperoxidase, annexins  are also involved in  the pathogenesis of 
Pemphigus. 91 
 
 
5. ROLE OF T CELLS  
 
It’s exact role in PV is not clear. But, autoreactive T- cell response to 
Dsg 3 may be critical in it pathogenesis.  These CD4 T cells produce Th2 
cytokines- Il-4 & Il-10. The Th2 dependant IgG4 subclass is predominant               
in active PV and Th1 dependant IgG 1 subclass is predominant during 
remission.92 
 
Recently, it has been demonstrated that a defect in the regulatory 
mechanism of Dsg 3 specific T cell leads to loss of tolerance of the B cells 
leading to autoantibody production.92 
 
 
DRUG INDUCED PEMPHIGUS 
 
Drugs causing pemphigus can be classified into 2  types 93 
a. Thiol/ SH group- penicillamine, captopril,piroxicam, etc 
b. Non thiol group- penicillin, ampicillin, amoxicillin, rifampicin, 
propanolol, phenytoin, phenobarbitone. 
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Among these penicillamine is the most commonest cause. 
Thiol group of drugs often induced Pemphigus, whereas the non thiol drugs 
trigger the disease in a predisposed individual.93 
 
NON DESMOGLEIN ANTIBODIES 
 
Autoantibodies to desmocollins have also been detected in few PV 
patients sera.94,95  
 
In a study, antibodies to e-cadherin has been detected, some but not all 
of which cross-react with desmoglein-1.96 
 
Apart from antibodies to cadherins antidesmoplakin  antibodies have 
been reported in severe pemphigus vulgaris.97  
 
 Antibodies to cholinergic receptors have been observed in pemphigus 
sera98 and cholinergic agonists has been shown to  inhibit acantholysis induced 
by pemphigus sera in vitro and have an apparent steroid-sparing effect in vivo 
in pemphigus.99  
 
 However, The significance of all the various antibodies in the 
pathogenesis of Pemphigus remain to be elucidated.100,101 
 
20 
 
CLASSIFICATION OF PEMPHIGUS 
 
1.   Pemphigus vulgaris 
 
      Variant: Pemphigus Vegetans 
 
2.  Pemphigus Foliaceous 
 
      Variants: Pemphigus Erythematosus 
                                     Pemphigus Herpetiformis 
 
3.   Induced pemphigus 
 
4  Intercellular IgA dermatosis 
 
5.  Paraneoplastic Pemphigus 
 
 
 
CLINICAL FEATURES 
 
Pemphigus vulgaris  can be divided in to two types102-  
 
• Mucosal dominant type:  with predominant mucosal erosions but 
minimal skin lesions;  
•  Mucocutaneous type:  mucosal involvement along with extensive bulla 
and erosions in skin. 
 
MUCOSAL INVOLVEMENT 
 
In  50 to 70% of patients have oral lesions are present.  It may precede 
the skin lesions by months or be the only manifestation of the disease.2,103,104 
 
Commonly, patients present with slow or non healing ill-defined 
erosions in the buccal or palatal mucosa with little or no surrounding 
inflammation. There is peripheral extension of the erosions with epithelial 
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shedding.105  In the oral cavity, intact bulla is rare. Other mucosa that can be 
involved are, the, oesophagus, nasal cavity, conjunctiva, pharynx, larynx, vulva 
cervix and urethra.106-111 
 
 Frequently superimposed candidial infection may be present.  
 
 
 
CUTANEOUS MANIFESTATION 
 
 Patients develop flaccid bullae with clear fluid over normal looking skin 
or an erythematous base. The content soon becomes turbid and ruptures to form 
erosions with peripheral extensions, which show little or no tendency to heal on 
its own. These erosions heal with hyperpigmentation.102 
 
 The skin lesions are predominantly seen over the axilla, groin, face, 
scalp, pressure bearing areas and trunk.102 
 
COMPLICATIONS 
 
Most common complication in pemphigus is secondary infection. If 
untreated it may even lead to sepsis and subsequently death.  
 
 The other complications are mainly related to the long-term treatment 
with steroids and other immunosuppressive agents. They include, adrenal axis 
suppression, cushingoid habitus, hypertension, fluid retention, osteoporosis, 
diabetes, cataracts, glaucoma, increased susceptibility to infections, and 
reactivation of tuberculosis. 
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PROGNOSIS OF PEMPHIGUS VULGARIS 
 The severity and natural history of pemphigus are variable. Advent of 
systemic steroids in the treatment of pemphigus has reduced the mortality to  
5% - 15%.2,113  The morbidity and mortality are related mainly to the disease 
severity, the prednisolone dosage required to induce remission, and some of 
these patients succumb to the complications of therapy and the presence of co-
morbidities.2,112,114–116.   Disease severity generally reduces with time and most 
relapses occur in the first 2 years.117  
 
Several prognostic factors have been identified for pemphigus, they include:118 
A. Type of pemphigus: PV and paraneoplatic pemphigus have the worst 
prognosis 
B. Age of the patient at disease onset: elderly patients have a poorer 
prognosis 
C. Race: The prognosis is worse in Jews.113 
D. Progression of disease prior to onset of treatment: patients with 
minimal disease activity for a longer time have better prognosis than 
those patients with rapid progression of the disease without 
treatment. 
E. Dosage of steroids required for disease control: patients who require 
higher dose of steroids with >180mg/day have a higher mortality 
rate. 
23 
 
F. Mucosal or skin involvement: those patients who initially have only 
cutaneous involvement than those with mucosal involvement have a 
better prognosis. 
G. Time of initiation of treatment: patient in whom steroids were started 
immediately, or within 6 months of onset of the disease had a better 
prognosis.  
 
SCORING SYSTEMS IN PEMPHIGUS 
 
 Due to the wide variation in the presentation of the disease, there is a 
need to devise certain objective parameters for evaluation of the disease 
progression or its response to therapy.  Hence, various scoring systems have 
been used, such as, Pemphigus Area and Activity Score, Pemphigus Activity 
score,  Pemphigus Disease Activity Index (PDAI), Autoimmune Bullous Skin 
Disorder Intensity Score(ABSIS), etc.119 
 
 Of all these scoring system PDAI score and ABSIS score are more 
commonly used. PDAI score combines mucosal and cutaneous disease in well-
defined anatomical location and also assesses the size and number of lesions, 
along with scoring for post-inflammatory hyperpigmentation.119 
 
 The main advantage of ABSIS score is that it is a quality- and quantity-
based score for oral mucosal and cutaneous lesions. This scoring system, 
monitors the clinical status of the patients over time.  
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 In addition, this system can be used for assessing other autoimmune 
bullous diseases, and thus is more versatile. 119 
 
PEMPHIGUS VEGETANS 
 It’s a variant of PV.  It’s of two types, the Neumann (severe) type and 
the Hallopeau (mild) type. The lesions are primarily seen in the flexures.  
 
 In Neumann type- initially vesicles and bullae develop which rupture to 
form hypertrophic granulating erosions, with easy bleeding. These lesions 
evolve into vegetating masses discharging pus and serum and the edges may be 
studded with small pustules.  New vegetative lesions may arise from erosions 
at the edge of the lesions, which eventually become fissured and 
hyperkeratotic. 
 
 In Hallopeau type- Pustules rather than vesicles are seen in the early 
lesions but they progress to vegetating plaques. 
 
SIGNS FOR PEMPHIGUS 
NIKOLSKY’S SIGN 
 Firm tangential pressure with a finger over a bony prominence will 
produce an erosion by separate normal looking epidermis from the dermis. It’s 
indicative of acantholysis. 
 Positive Nikolsky sign is indicator of active disease.120 
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BULLASPREAD SIGN/ LUTZ SIGN 
 Unidirectional pressure applied by a finger causes peripheral extension 
of the bulla beyond the marked margin.120  
 
ASBOE HANSENS 
 Pressure is applied to the centre of the bulla which causes peripheral 
extension beyond the marked margins.120 
 
INVESTIGATIONS 
1. TZANCK SMEAR 
 It is a useful bedside test for diagnosis of pemphigus.120  The intact roof 
of the blister is separated and the floor of the blister is scraped using a  scalpel. 
The material obtained, is then placed over a glass slide and tzanck smear is 
done with Giemsa stain. 
 
 The smear shows multiple acantholytic cells. It is a rounded keratinocyte 
with a hypertrophic nucleus and hazy or absent nucleoli, increased nuclear to 
cytoplamic ratio with peripheral condensation of the cytoplasm (mourning 
edged cell), causing a perinuclear halo.120   
 
 Other findings that can be detected in Tzanck smear include sertoli’s 
rosette and streptocytes. 
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 Sertoli’s rosette refers to a central keratinocyte surrounded by 
leucocytes. Streptocytes refers to arrangement of leucocytes in chains. 
 
 In PF the acantholytic cell is smaller, less rounded, or cuboidal shaped 
with a small nucleus and abundant cytoplasm. The cells may have 
keratohyaline granules and show keratinization. 
 
 
2. SKIN BIOPSY AND HISTOPATHOLOGY 
 Biopsy for H&E staining should be done from an early intact bulla or 
vesicle.   
  
 The earliest change in PV is may be rarely, eosinophilic spongiosis and 
most commonly spongiosis in the supra basal layers, which is considered as the 
earliest manifestation of acantholysis.121 
 
 This acantholysis initially leads to formation of cleft followed by bulla 
in the supra basal layers.121 
 
 In a well developed lesion, suprabasal bulla with acantholysis and 
acantholytic cells in the blister cavity is noted. Basal keratinocytes show the 
characteristic tomb-stone appearance. This is because basal keratinocytes show 
loss of  adhesion with adjacent keratinocytes but remains attached to the 
basement membrane. The intraepidermal acantholysis may sometimes involve 
the adnexal structures. 121 
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 There is little inflammatory infiltrate during the early stages of the 
blister, with superficial dermis showing perivascular lymphocytic infiltrate and 
dermal edema. However, if eosinophilic spongiosis is present in the early 
stages predominantly eosinophilic infiltrate is seen in the dermis. 121 
 Several changes occur in the late stages of the bulla. The dermis shows 
mixed inflammatory infiltrate of neutrophils, lymphocytes, eosinophils and 
macrophages. The bulla may rupture to form an erosion or an ulceration with 
the base showing acantholytic cells.121 
 Sometimes an older bulla may show several layers of epidermis at the 
base due to keratinocyte migration and proliferation.  Lastly, there may be 
down growth of the epidermis giving rise to villi.121  
 In case of an oral mucosal biopsy it’s difficult to demonstrate an intact 
bulla. Hence, only erosions and ulcerations of the mucosa is detected. And 
biopsy is taken from the edge of the erosion with intact adjacent mucosa in 
order to demonstrate the typical pathological findings.121 
 
Pemphigus Vegetans 
 Histopathology shows suprabasal cleft and the vegetating lesions show  
hyperkeratosis, papillomatosis and acanthosis. Some bulla may contain 
eosinophils and few acantholytic cells are present. In older lesions, eosinophilic 
abscesses may be present in the epidermis.  In the early pustular lesions of the 
Hallopeau type, eosinophilic spongiosis or microabscesses are common. With a 
heavy of lymphocytic and eosinophilic infiltrate with few neutrophils in the 
dermis.122 
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3. IMMUNOFLUORESCENCE 
 Immunofluorescence is a laboratory technique used for demonstration of 
the presence of tissue-bound and circulating antibodies.  Both direct and 
indirect immunofluorescence can be done for the diagnosis of pemphigus. 
Direct immunofluorescence of skin or mucosa for the detection of anti-
desmoglein 3 and / or 1 antibodies is considered as the gold standard in the 
diagnosis of pemphigus.   
 
The sample for direct immunofluorescence  is obtained from the 
perilesional skin or mucosa. 
 
History  
It was in the year 1941, that Coons et al first developed the 
immunofluorescence technique with a blue fluorescing compound, β 
anthracene, which made it possible to visualize the microscopic antigens, 
antibodies and other elements in tissue sections or cell smears.123 
 
 Diagnostic immunopathology in dermatology began in the year 1963, by 
the demonstration of complement and immunoglobulins deposition in the 
dermo-epidermal junction of skin - Lupus band test in SLE.124 
 
 In 1964, Beutner and Jordon demonstrated antibodies in the sera of 
pemphigus patients by indirect imunofluorescence.4 
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 In 1971, Jordon et al. demonstrated the deposition of IgG antibodies at 
the inter-cellular spaces in the epidermis by direct immunofluorescence of the 
lesional and perilesional skin.125  
 
Principle Of Fluorescence 
 Fluorescence is the light emitted by the singlet state of molecule on 
returning to its ground state, following absorption of photon from an external 
source. 
126
 
 
 
 
Figure -5 
A) Electron its in ground state in a molecule 
B) Electron excited by a high energy light- UV light and attains a higher 
energy state 
C) Electron unable to maintain its high energy state and drops to its lowest 
singlet energy state by losing energy as heat. 
D) The electron then spontaneous returns to its original ground state by 
emitting the remaining energy as light with longer wavelength and lesser 
energy in the form of fluorescence, 
ELECTRON 
B- INCIDENT UV  LIGHT C- HEAT LOSS D- FLUORESCENCE A- NORMAL  MOLECULE 
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BASIS OF IMMUNOFLUORESCENCE 
 
 In this technique, the antibodies, antigens or their complexes are stained 
with corresponding antibodies tagged with a fluorochrome and viewed under 
an fluorescent microscope with a mercury vapour or xenon light source and 
appropriate exciter and barrier filters.127 
 
 Fluorochromes are substances which can absorb light of a particular 
wavelength and attain an unstable higher energy state. Then on spontaneously 
returning to their original state, they re-emit light with longer wavelength.128 
 
Fluorochromes currently in use:128 
 Fluorescein Isothiocyanate (FITC) -  Produces apple green fluorescence 
 Tetramethyl Rhodamine isothiocyanate (TRITC) -  Produces red colour 
fluorescence 
 Phycoerythrin – Produces red fluorescence 
 
The FITC is linked with antibodies by a thiocarbamide linkage without 
interfering with their antigen binding capacity. 129 
 
TYPES OF IMMUNOFLUORESCENCE 
1. Direct Immunofluorescence 
2. Indirect Immunofluorescence 
3. Complement Indirect Immunofluorescence 
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1. Direct immunofluorescence  
 It’s a single step method, where the antibody specific to the target 
molecule is tagged with a fluorescent dye. 
 
 In case of auto-immune blistering disorders FITC tagged anti- 
immunoglobulin antibodies are used for the detection of in-vivo antibodies 
bound to the target antigen. For direct immunofluorescence sample is generally 
transported in michels medium where it can be stored for upto one month at  4 - 
8ºC.130,131   However, if sample is to be quick frozen immediately, it in can be 
transported in PBS medium. 
 
 
2. Indirect immunofluorescence 
 It’s a two step procedure, used to detect the circulating antibodies in the 
patients serum. In this procedure the antibody specific to the target molecule: 
the primary antibody is unlabeled, and a second anti-immunoglobulin antibody 
called the secondary antibody is directed toward the constant portion of the first 
antibody- is tagged with the fluorescent dye.130, 131 
 
 In case of autoimmune blistering disorder, First a substrate is incubated 
with the patients serum and then the FITC tagged anti-immunoglobulin 
antibodies are added for detection of the pathogenic antibodies.128 
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3. Complement Indirect immunofluorescence  
  
 This is another type of IIF. It’s a 3 step technique, in which the patients 
serum is incubated with the substrate, then  complement is added.  Fluorescein 
labelled anti-complement antibodies are then added to detect the presence of 
complement in the tissue. This test is done to detect complement fixing 
antibodies.132 
  
 The practical use of this technique is mainly limited to the diagnosis of 
Pemphigoid Gestationis. 132 
 
DIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
 
 Direct immunofluorescence is considered as gold standard in the 
diagnosis of pemphigus with a sensitivity of 95-100% 132,133 
 
 DIF shows deposition of IgG and/ or C3 against desmoglein 3 and / or 1 
in the epidermal intercellular spaces. This is described as ‘lace-like’ or 
‘chicken-wire’ or ‘fishnet’ pattern. In late lesions when the acantolytic cells are 
well developed the classical ‘fish-net’ pattern of immunofluorescence may 
become dot-like, corresponding to the  aggregation of desmosomes on the cell 
surface.133 
 
 The DIF staining shows IgG antibodies in 100 % of positive cases and 
C3 in 50-100%. 132  IgA and IgM may be present, but less frequently.102 
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 In Patients with active P.V, both IgG1 and IgG4 subclasses of antibodies 
are seen, but the IgG4 is pathogenic.74,75 
 
 The intensity of DIF staining correlates with the disease activity. 
However, in few patients it may be positive even when the patient is in clinical 
remission.132 
 
 In pemphigus vulgaris patients, negative DIF may be an indicator of 
immunological remission. And repeated negative DIF during clinical remission 
may be considered as a possible sign for apparent cure of the disease, and 
treatment may be discontinued in such group of patients.13-16  
 
False positive DIF 
 It is very rare, but non-specific intercellular staining can be seen in 
psoriasis, spongiotic dermatitis, bullous impetigo, and epidermis adjacent to 
ulcers secondary to any cause may have squamous intercellular substance IgG 
as the intercellular space may contain serum. 133 
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DIRECT IMMUNOFLUORESCENCE OF HAIR 
 
 The scalp is a commonly involved site in Pemphigus. Wilson et al, 
demonstrated that, in the scalp, the outer root sheath hair follicle and the 
dermal bulb matrix cells is rich in the target antigens of pemphigus. This may 
be the reason for scalp involvement in pemphigus.134 
 
 Recently, it has been shown that outer rooth sheath of hair follicle which 
is structurally similar to the epidermal keratinocytes also shows positive direct 
immunofluorescence findings with a sensitivity of 85-100%.17-20 
 
 Schaerer and Trueb in the year 2003, for the first time, demonstrated 
pemphigus specific DIF pattern in the ORS of the hair follicle of the plucked 
hair. They demonstrated positive DIF findings in 100% of their patients.17 
 
 Similarly another study demonstrated acantholysis in the hair follicle 
and also immune deposits specific to Pemphigus in the outer root sheath and 
matrix of hair follicle in the biopsy specimens.134 
 
 Another study on 50 patients with Pemphigus, characteristic DIF 
findings were seen in the outer root sheath of both telogen and anagen hair 
follicle in 100 % of patients irrespective of scalp involvement, they also 
demonstrated that  positive DIF findings were also seen in the body hairs.20 
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INDIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
 
 In this method circulating IgG antibodies are demonstrated in 80-90% of 
pemphigus cases.133   The substrates commonly used for IIF include guinea pig 
oesophagus, monkey oesophagus and normal human skin. Of which money 
oesophagus is considered as the ideal substrate.133 
  
 IIF has been widely used for monitoring of the serological activity of 
pemphigus patients. It has been demonstrated that the antibody titres in the 
patients sera in many instances, correlates with the disease severity.4-8 
However, other studies analyzing the serial titers by IIF, showed that the 
antibody titers do not always correlate with disease severity and hence, cannot 
be used as a guide to prognosis or monitoring the disease activity.8-12 
 
 Judd and Lever found that administration of a high dose of daily steroids 
resulted in clinical improvement as well as showed a marked fall in the titer of 
circulating antibodies. However, there was no predictable correlation between 
the disease activity and antibody titer by IIF when the patients were not 
receiving a high dose of steroids.10 
 
False positive IIF 
 False positive immunofluorescence staining can be seen in burns, 
penicillin allergy, toxic epidermal necrolysis, bullous pemphigoid, myasthenia 
gravis, SLE, lichen planus, cicatricial pemphigoid and in patients with 
antibodies against blood group A and B.133  
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ADVANTAGES  IMMUNOFLUORESCENCE 
 
1. Its used for laboratory diagnosis of various dermatological disorders. 
2. Various auto immune disorders with similar clinical picture are 
classified using immunofluorescence. 
3. Confirmation of diagnosis in cases where the clinical picture is atypical 
or non specific. 
4. Circulating antibody level detected by IIF can be used as a prognostic 
marker and also as a marker of disease activity and response to 
treatment in patients diagnosed with pemphigus. 
5. Antigen mapping can be done, which play an important role in 
classification of various form of hereditary epidermolysis bullosa. 
 
 
DISADVANTAGES OF IMMUNOFLUORESCENCE  
 
1. Expensive procedure and requires a lab with cryostat for frozen sections 
and a deep freezer for the storage of these specimens, with a well trained 
technician and  a pathologist proficient in the performance and 
interpretation of the results of immunofluorescence.  
2.  DIF stained slides cannot be stored for long-term, as the fluorescent 
stained slides quenches rapidly on exposure to sun light. 
3. False positive DIF and IIF can occur. 
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LIMITATIONS OF IMMUNOFLUORESCENCE TECHNIQUES 
 
1. Photobleaching 
It refers to the photochemical reaction which causes reactive oxygen species 
mediated destruction of a fluorochrome in the specimen. It can be reduced  by 
decreasing intensity and duration of excitation light, using a low concentration 
of a fluorochrome and addition of singlet oxygen scavengers. 
 
2. Autofluorescence 
 It is due to flavin coenzymes and reduced pyridine nucleotides. Fixation 
with aldehydes, particularly glutaraldehyde, can increase autofluorescence. 
 
3. Fluorescence Overlap 
 The emission signals may sometimes over lap if more than one colour 
fluorescence is emitted. 
 
ANTI-DESMOGLEIN ELISA TITRES 
  Recently, a sensitive and specific ELISA assay with recombinant dsg 1 
and dsg 3 for serodiagnosis of pemphigus has been used. Anti-desmogleins 
ELISA assay has shown that 95% of PV patients have desmoglein-3 antibodies 
and around 50% have desmoglein-1 antibodies. It has been shown recently that 
in appropriate dilutions, antidesmoglein-1 ELISA assays can also be used to 
monitor disease activity.3 
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 Many studies have demonstrated that anti-desmoglein ELISA titres has a 
better correlation with disease activity than IIF.138 
  
OTHER INVESTIGATIONS 
 
 Apart from these diagnostic investigations in pemphigus, various 
baseline investigations such as a complete blood count, Urine routine, Liver 
function Test, Renal function test Fasting and post prandial blood sugar, chest 
X Ray, Mantoux test are done to rule out secondary infection, pulmonary 
tuberculosis and other co- morbidities prior to starting the treatment. 
 
 
TREATMENT OF PEMPHIGUS 
 
 Pemphigus vulgaris if untreated is a fatal disease with mortality as high 
as 75% in the pre corticosteroid era.139 
 
 Currently, systemic corticosteroids with or without adjuvant 
immunosuppressive agents are considered as the first-line treatment of 
pemphigus. 
 
Objectives of treatment: 
 
a) Healing of the cutaneous and mucosal erosions.  
b) To prevent or decrease the  recurrences; 
c) To  improve the patients quality of life; 
d) Maintenance of remission with the least dosage of steroids or other 
immunosuppressives, in order to limit adverse effects of treatment. 
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 First step in the management of pemphigus, is assessing the patients 
general condition,  extent and severity of the disease and also presence of 
secondary infection and fluid and electrolyte imbalances. 
 
Followed by supportive care. This includes. 
1. Proper nursing care: Regular cleaning and dressing without extensive 
desloughing of the erosions until re-e pithelisation. This can be done by 
dressings with sterile petrolatum/ antibiotic gauze.  Measures should be 
taken for prevention of bed sores. And finally maintenance of proper 
oral hygiene. 
 
2.  Nutrition: patient requires a soft, high protein and calorie diet as there 
may be loss of proteins and also patient may be unable to eat due to 
severe oral ulcerations. If patient is not able to take oral feeds patient 
may require a feeding tube or parenteral nutrition. 
 
3. Control of secondary infection:  And if necessary antibiotics and anti 
fungal need to be added. 
 
4. Correction of fluid and electrolyte imbalances: Patient may also have 
significant fluid and electrolyte imbalances due to extensive erosions 
and in such conditions IV fluids should be administered.  
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SYSTEMIC CORTICOSTEROIDS 
 Corticosteroids are the first line treatment for pemphigus. 
 
 Prednisolone is the most widely used and therefore the preferred drug. 
Other steroids such as methylprednisolone, deflazacort, dexamethasone and 
betamethasone have also been used.  
 
 The optimum dosing schedule of corticosteroid is not known and the 
dosing is largely based on various studies.   
 
 For mild to moderate disease steroids are usually started at a dose of 60-
80mg/day and for a severe disease 80- 120mg/day.140 If there’s no clinical 
improvement in 1 week then the dose can be escalated every 4-7 days until the 
disease is under control. Once 80-90 % of the lesions have healed, the dose can 
be tapered by 50% every 2 weeks and maintain the patient on the minimal dose 
of steroid required for maintenance of clinical remission.141 
 
 On an average, appearance of new lesions stops within 2–3 weeks of 
starting treatment and full healing takes 6–8 weeks.142-45 
 
 Although corticosteroids cause rapid resolution of the lesions it cannot 
be administered in high doses on long term due to its significant adverse 
effects. One study had shown that upto 77% of the deaths in pemphigus was 
related to corticosteroids.2 Hence, adjuvant immunosuppressives are added in 
order to reduce the dose of CS required and also its related side effects.  
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Table - 2 
ADVERSE EFFECTS OF LONG TERM STEROIDS146 
CATEGORY ADVERSE EFFECTS 
Cutaneous Steroid induced acne, rosacea, increased 
susceptibility to cutaneous infections, 
delayed wound healing, striae, telogen 
effluvium, hirsutism, fat atrophy 
Glucocorticoid effects Hyperglycemia, increased appetite and 
weight gain 
Mineralocorticoid effects 
(due to sodium retention and 
potassium loss) 
Hypertension, congestive heart failure, 
arrhythmias secondary to hypokalemia, 
weight gain 
Lipid effects Hypertriglyceridemia, cushingoid habitus, 
menstrual irregularity 
Bone  Osteoporosis, osteonecrosis, indirect 
hypocalcemia 
Gastrointestinal  Peptic ulcer disease, bowel perforation, fatty 
liver, esophageal reflux, nausea, vomiting 
Ocular  Cataract, glaucoma, infection especially 
staphylococcus 
Psychiatric  Psychosis, agitation, personality changes, 
depression 
Muscular  Myopathy  
Neurologic  Pseudotumor cerebri, epidural lipomatosis, 
peripheral neuropathy 
Infections  TB reactivation, oppurtunistics infections 
like deep fungal, etc.  
Pediatric  Growth impairement  
Pulse therapy  Immediate flushing of face, hiccups, muscle 
weakness, asthenia,electrolyte shifts, cardiac 
dysarrythmias, seizures. 
The long term side effects are similar to 
daily steroid administration. Though its 
comparatively lower with pulse therapy   
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DEXAMETHASONE CYCLOPHOSPHAMIDE THERAPY 
 In order to overcome the side effects of long term steroids, pulse therapy 
was used. 
 
 Pulse therapy with steroids refers to administration of 
suprapharmacological dose of steroids as a bolus dose over a short period of 
time and then completely withdrawing it until the next dose.  
 
 Parischa et al in the year 1982 first proposed the Dexamethasone and 
cyclophosphamide pulse therapy for pemphigus.147 
 
ADVANTAGES OF DCP THERAPY 
• It induced faster clearance of lesions,  
• faster disease control, 
• lower cumulative dose of CS required and reduced side effects of 
corticosteroid therapy.  
 
DCP regimen has 3 phases: 147 
Phase - I 
 Dexamethasone  100mg in 500ml of 5% dextrose over 3 hours for 3 
consecutive days and Cyclophosphamide 500mg in 500ml of % dextrose on 
day 2 with daily 50mg cyclophosphamide. The same cycle is repeated every 28 
days until the patient is in clinical remission.  Oral Steroids may be added if 
disease is not under control.  
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Phase - II 
 DCP pulse therapy with daily oral CYP is continued for 9 months after 
clinical remission. 
 
Phase - III 
 DCP pulse therapy is stopped and daily oral Cyclophasphomide is 
continued 
 
Phase - IV 
 After stopping treatment the patient is followed up for a period of 10 
years for recurrences.  
 
ADJUVANT IMMUNOSUPRESSIVES 
 The two, first line adjuvant immunosuppressives are cyclophosphamide 
and azathioprine. Others include, mycophenolate mofetil, cyclosporine, 
dapsone, methotrexate 
 
CYCLOPHOSPHAMIDE 
 
   Cyclophosphamide has been used as an adjuvant to CS and is usually 
given at a dose of 1-3 mg/kg body weight. 
 
 Monthly IV cyclophosphamide in DCP pulse therapy with daily oral 
Cyclophosphamide in low doses has been used with success.152,154,155 
44 
 
 Various studies have shown that treatment with steroids and CYP as 
adjuvant showed better results than with steroid alone.147-149,154 
 
 However,  it should be used with caution in women of child bearing age 
and in patients who have not yet completed their family, as it’s known to cause 
secondary infertility due to amenorrhoea and azospermia, on long-term 
administration.151 
  
 A study has shown that remission in pemphigus can be maintained with 
low dose of Cyclophosphamide alone.152 
  
 Hence, according to BAD guidelines cyclophosphamide can be used as 
an alternative to Azathioprine.  
 
AZATHIOPRINE 
 It’s usually given at a dose of 1-3m g/kg/ day. However, ideally 
azathioprine dose should be tailored according to the TPMT levels. 
  
 The therapeutic effect of azathioprine is often seen only after 3-5 weeks.  
According to BAD guidelines, azathioprine is considered as the drug of choice 
for adjuvant therapy.  
  
 In terms of mortality and remission, Prednisolone with azathioprine   is 
more effective than Prednisolone alone. 147,153,154 
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MYCOPHENOLATE MOFETIL 
 
 MMF is usually given at a dose of 2-2.5g/day as a steroid sparing agent. 
One randomized controlled trial found MMF to be a less effective than 
azathioprine as a steroid sparing agent156, while another smaller trial found no 
difference in efficacy between the two.2 
 
METHOTREXATE 
 
 It can be considered as an adjuvant, if the more commonly used steroids 
sparing agents cannot be used for the patient. Earlier studies with high dose 
methotrexate showed high mortality rate.148  However, a recent study has 
shown that methotrexate can be useful and well tolerated in pemphigus patients 
with a considerable steroid sparing effect.158  And another study with 2  
recalcitrant cases of pemphigus showed good response with dexamethasone 
pulse therapy and methotrexate as an adjuvant.159 
 
CYCLOSPORIN 
 Initial there were case reports that cyclosporine was a useful adjuvant 
with  considerable steroid-sparing effects in PV.160-162   However, a recent trial 
has found that cyclosporine as an adjuvant therapy has no benefit over steroids 
alone.163 
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 Hence, according to BAD guidelines it is not recommended as an 
adjuvant in pemphigus. 
 
DAPSONE 
 Dapsone at a dose of 100-200mg/ day has been tried as an adjuvant in 
pemphigus.157  It has been found to be effective as a steroid sparing agent in 
few studies.164 
 
TETRACYCLINES AND NICOTINAMIDE 
 A combination of tetracycline 2g/day and nicotinamide1.5g/day has 
been shown to control the disease in 2 of 6 patients with PV. Minocycline and 
tetracycline has also been used as an adjuvant with steroids. 157 
 
RITUXIMAB 
 It is a chimeric monoclonal anti CD 20 antibody. Its effect, is mainly on 
the B cells.  
 Two studies, have provided valuable data regarding the safety and 
efficacy of rituximab. A study conducted by cianchini et al , showed that 86 % 
of patients treated with Rituximab achieved clinical remission and discontinued 
steroid within 6 months.167 And a study by Reguiai et al with 13 Pemphigus 
patients treated with Rituximab achieved clinical remission within the first 3 
months.166  
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Rituximab can be administered by two different protocol:166 
 The lymphoma protocol- 375mg/m2 BSA IV weekly for 4 weeks. 
 The rheumatoid arthritis protocol-  1g IV at an interval of 15 days. 
 
 However, the major concern for rituximab is its adverse effects such as 
neutropenia, increased susceptibility to infections, sepsis, DVT. 
 
IVIG 
 IVIG at a dose of 2g/kg body weight divided over 3 days has been tried, 
this cycle is repeated every 4 weeks.157 A study showed that a minimum of 3 
cycles of IVIG produced beneficial effects in 81% of patients with refractory 
pemphigus. Cost is the major limiting factor. 
 
 Other treatment options that have been tried in the Pemphigus include 
Gold, pyridostigmine bromide (a cholinergic agonist), biological such as 
infliximab and etanercept and procedures such as plasmapheresis, 
immunoadsorption and extracorporeal photopheresis.157 
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MATERIALS AND METHODS 
 
 
 It’s a hospital - based prospective study. 
 
 The study was done with patients diagnosed as a case of pemphigus 
vulgaris, attending the outpatient clinic in the Department Of 
Dermatology, Venereology, Leprosy, PSG IMS & R, Coimbatore. 
 
 The study was conducted over period of one year after obtaining 
institutional ethics committee approval was obtained prior to the 
commencement of the study. 
 
 Informed and written consent was obtained from all the patients and 
from the histopathology department, PSG IMS & R, where the 
investigations were done. 
 
 The patients were then tested for direct immunofluorescence of skin and 
Hair. 
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INCLUSION CRITERIA 
• Patients  with Pemphigus Vulgaris who showed intercellular deposition of 
IgG antibodies against Dsg3 and/or  Dsg1 and/or C3  in DIF of  skin and 
hair during the active stage of disease were included in the study 
• The patients had no new or non-healing skin or mucosal lesions in the past 
6 months or more. 
• And were On Daily prednisolone dosage equal to or less than 10mg 
• And/or adjuvant immunosuppressive therapy like azathioprine 50mg or 
cyclophosphamide 50mg. 
 
EXCLUSION CRITERIA 
• Patients with new or non healing skin or mucosal lesions in the preceding 6 
months 
• Patients with other bullous disorders. 
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Table - 3 
METHODOLOGY FLOWCHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 patients with pemphigus vulgaris in clinical remission for 6 
months or more were included in the study 
 
Informed and written consent was obtained 
History and physical examination was done 
Data was recorded in the datasheet 
Skin sample was obtained from the patients upper trunk 
hair sample was obtained in the same way as for a trichogram 
The distal end of the hair shaft with the bulb and outer rooth sheath 
is cut to about 2 cm. 
 
The shortened anagen hair type was further confirmed by 
microscopy 
 
Skin and hair sample is transported immediately in the PBS medium 
to histopathology lab and subjected to  direct immunofluorescence 
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1. METHOD OF DIRECT IMMUNOFLUORESCENCE OF SKIN 
 
1. A punch Biopsy specimen from the skin is received in the PBS medium 
2. Specimen is then snap frozen in the cryostat 
3. 5 frozen sections of 5µm thickness each is cut using a cryotome and 
placed on the slide 
4. Fan dry the section for 10 minutes 
5. The section is then washed in PBS at 7.4 pH for 10 minutes 
6. Fan dry the section for 10 mins 
7. Each of the slide is then incubated in room temperature for 1 hour with 
one of the following FITC-labeled antisera - IgG & Fibrinogen each 
diluted 1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS (The 
PBS used in the above steps contains Propidium iodide which is a 
Counter-stain ) 
8. Wash the slides 3 times with PBS for 10 minutes each 
9. Fan dry the sections 
10. Mount in buffered glycerol 
11. Examine under fluorescent microscope. 
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2. METHOD FOR DIF OF HAIR 
1. The hair sample is received in PBS medium to the histopathology lab. 
2. Hair sample is placed over a Glass slide 
3. Washed three times with PBS medium for 10 minutes each 
4. Then the specimen is fan dried 
5. Each of the slide is then incubated in room temperature for 1 hour with 
one of the following FITC-labeled antisera - IgG & Fibrinogen each 
diluted 1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS 
(The PBS used in the above step contains Propidium iodide which is a 
Counter-stain) 
6. Wash the slides 3 times with PBS for 10 minutes each 
7. Fan dry the sections 
8. Mount in buffered glycerol 
9. Examine under fluorescent microscope. 
 
 Based on the presence or absence of immunofluorescence deposits in the 
specimen the results were interpreted as positive or negative. 
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RESULTS 
 
Table - 4 
ATIENTS CHARACTERISTICS 
 
 
 
 
 
 
 
 
Total No. of patients (n)  30 
Age (years)  Mean±SD  44.83 ± 13.27 
Sex -  female:male  19:11 
Phenotype of disease Mucocutaneous (n)  30 
History of scalp involvement (n)  30 
Duration of disease (months)  Mean±SD  45 ± 16.87 
Duration of remission(months)  Mean±SD  32.512 ± 23.61 
DIF positive with either substrate  16 
No. of patients on treatment  17 
No of patients not on treatment  13 
No. of positive hair DIF  14 
No of positive skin DIF  10 
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Figure - 6 
 
 
 The age of patients in our study ranged from 17-69 years with a mean 
age of 44.34 years 
 
 Majority (33.3%) of the patients in our study were in the age group of 
41-50 years.  
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Figure - 7 
 
 Our study showed a female preponderance with a male-female ratio of 
1:1.7 
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Figure - 8 
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Figure - 9 
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Figure - 10 
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Figure - 11 
59 
 
 
Table – 5 
 
FREQUENCY OF HAIR AND SKIN DIF IN PEMPHIGUS 
PATIENT IN CLINICAL REMISSION 
 
Hair test 
Skin test P Value 
(Chi square test) Positive Negative 
Positive 
8 
57.1% 
6 
42.9% 
.010 
significant 
Negative 
2 
12.5% 
14 
87.5% 
 
 
 Of the total 30 patients, 16 patients had a positive DIF findings with 
atleast either one of the substrate. 
 The findings of hair skin DIF correlated with each other in 22 patients. 
 The sensitivity of hair DIF in our study was 80% 
 The specificity of Hair DIF was 70 %  
  There was a statistically significant association between skin and hair 
DIF findings with a p value of 0.010. 
 Positive Predictive value was 57.14%. 
 Negative Predictive value was 87.5%. 
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 Figure - 12 
 
 
 
 As seen above, hair DIF was positive in 14 patients whereas skin DIF 
was positive only in 10 patients 
 
 And Hair DIF was negative in 16 patients whereas skin was negative in 
20 patients. 
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Figure - 13 
 
 
 
 Of the 14 patients with positive hair DIF, 8 patients also had positive 
skin DIF. 
 
 
 However, in 6 patients hair DIF  was positive but skin was negative. 
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Table -  6 
 
ASSOCIATION BETWEEN HAIR DIF AND DURATION OF DISEASE 
 
DIF Of Hair N 
Duration of disease 
Mean±SD 
P Value 
Positive 14 41.57±30.09 .828 
Not significant Negative 16 48.00±35.18 
 
 
Table -  7 
 
SKIN DIF AND DURATION OF DISEASE 
 
 
 
 Patients with negative hair and skin DIF had a longer disease duration.   
 
 There was no statistically significant association between  mean disease 
duration and hair & skin DIF.  
 
 
 
DIF Of Skin N 
Duration of disease 
Mean±SD 
P Value 
Positive 10 38.70 ± 29.564 
. 680 
Not significant Negative 20 48.15 ± 34.176 
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Table -  8 
 
 
HAIR DIF AND DURATION OF REMISSION 
 
 
 
 
 
 Patients with positive hair DIF and a shorter duration of remission 
compared to patients with negative DIF. 
 
 However, the association between hair DIF and duration of remission 
was not statistically significant. 
 
 
 
 
DIF Of Hair N Duration of Remission Mean±SD 
P Value 
(independent T 
test) 
Positive 14 12.43±12.10 
0.072 
Not significant 
Negative 16 20.75±30.273 
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Table -  9 
 
SKIN DIF AND DURATION OF REMISSION 
 
 
 
 
 Patients with positive skin DIF and a shorter duration of remission 
compared to patients with negative DIF. 
 
 However, the association between skin DIF and duration of remission 
was not statistically significant. 
 
 
 
  
 
 
 
 
 
 
DIF Of SKIN N 
Duration of Remission 
Mean±SD 
P Value 
(independent T test) 
Positive 10 16.8±19.96 
0.931 
Negative 20 16.9± 25.735 
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Table – 10 
 
Hair DIF AND CURRENT TREATMENT 
 
 
 
 
 
 Hair DIF was positive in 50 %  patients and negative in 50 %  of 
patients who were currently not on treatment, 
 In Patients who were on treatment Hair DIF was positive in 44.4  %  and  
negative in 55.5 %. 
 Hence, in patients on treatment Hair DIF negativity was slightly higher. 
 However, the association between Hair DIF and current treatment was 
not statistically significant. 
 
 
Current treatment 
Hair dif 
P value 
(chi square test 
Positive Negative 
0.765 
NOT SIGNIFICANT 
Not on treatment 6 
50% 
6 
50% 
 
On treatment 8 
44.4% 
10 
55.5% 
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Table – 11 
 
 
SKIN DIF AND CURRENT TREATMENT 
 
 
 
 
 
 Skin DIF was positive in 41.6 % of patients and negative in 58.3 % of 
patients who were currently not on treatment, 
 In Patients who were on treatment Skin DIF was positive in 27.7 % 
patients and negative in 72.2 % patients.  
 Hence, in patients on treatment skin DIF negativity was slightly higher. 
 However the association between skin DIF and current treatment was 
not statistically significant. 
 
 
 
 
 
 
  
Current treatment SKIN DIF P Value 
(CHI SQUARE TEST 
Positive Negative 
0.429 
NOT SIGNIFICANT 
Not on treatment 5 
41.6% 
7 
58.3% 
On treatment 5 
27.7% 
13 
72.2% 
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Table – 12 
 
 
SKIN AND HAIR DIF FINDINGS IN PATIENTS NOT ON 
TREATMENT 
 
 
 
 
 Of the 30 patients, 12 patients were not on treatment. 
 
 Positivity with either substrate was seen in 7 patients. 
 
 And hair DIF was positive in 6 patients whereas skin DIF was positive 
only in 5 patients. But it was not statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hair DIF 
SKIN DIF 
P Value 
(CHI SQUARE TEST 
Positive Negative 
0.0789 
NOT SIGNIFICANT 
Positive 4 2 
Negative 1 5 
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Table – 13 
 
 
ASSOCIATION BETWEEN DURATION OF REMISSION  AND 
GENDER 
 
 
 
 The Female patients had a longer duration of remission (20.16 
months)compared to the males(11.18 months) in our study. 
 And the association was found to be statistically significant with a p 
value of 0.05. 
 However, it should be emphasized that our study had a female 
predominance and the disease duration was also widely variable. 
 
 
Gender N 
Duration of Remission 
Mean±SD 
P Value 
(independent T test) 
Male 11 11.18 ±8.28 0.05 
Significant 
Female 19 20.16 ± 28.799 
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Table – 14 
 
ASSOCIATION BETWEEN HAIR DIF FINDINGS IN REMISSION 
AND GENDER 
 
 
 
 
 
 
 
 
 
 
Gender 
Hair DIF 
P Value 
(CHI SQUARE 
TEST 
Positive Negative 
0.156 
NOT 
SIGNIFICANT 
Male 7 
63.6% 
4 
36.4% 
Female 7 
36.8% 
 
12 
63.2% 
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Table – 15 
 
ASSOCIATION BETWEEN SKIN DIF FINDINGS IN REMISSION AND 
GENDER 
 
 
 
 There was no statistically significant association between gender and 
positivity of hair and skin DIF findings respectively, in remission.  
 
Gender 
SKIN  DIF 
P Value 
(CHI SQUARE TEST 
Positive Negative 
0.789 
NOT SIGNIFICANT 
Male 
4 
36.4% 
7 
63.6% 
Female 
6 
31.6% 
13 
68.4% 
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DISCUSSION 
 
 Pemphigus is a chronic autoimmune bullous disorder characterized by 
autoantibodies against desmogleins 3 and/ or 1.1 Steroids alone or with 
adjuvant immunosuppressives are the mainstay of treatment. The main goal of 
treatment is to maintain clinical remission with the least dosage of the 
immunosuppressives and eventually withdraw treatment when the patient has 
attained clinical and immunological remission. However, till date, there are no 
firm protocols devised for discontinuation of treatment. Various modalities 
currently available for assessment of immunological remission include anti-
desmoglein ELISA titres, direct immunofluorescence and indirect 
immunofluorescence.3-8 According to the British guidelines, treatment can be 
withdrawn primarily based on the clinical status of the patient, and 
immunofluorescence findings may aid the decision. 
 
 But , anti-desmoglein ELISA titres are expensive and not available in all 
clinical settings. And currently, IIF has much less value in assessment of 
disease activity as studies have shown that high dose steroids can cause rapid 
fall in the antibody titres and also, that they do not always correlate well with 
the disease activity.9-12 
 
72 
 
 David M et al in 1989, based on their study suggested that repeated 
negative DIF in pemphigus patients on clinical remission could be a sign of 
immunological remission.13 Similar findings were also reported by Balighi et 
al. and Ratnam et al.15,16 
 
 Ratnam et al, also noted that the patients with positive DIF findings 
during clinical remission had a significantly higher relapse rate after the 
discontinuation of treatment.16  
  
 Various studies have shown that the rate of relapse was about 44-100 % 
in patients with positive DIF findings during remission and 13-27% in patients 
with negative DIF.13,14 
 
 Wilson et al. in 1991, demonstrated that the human hair follicle is rich in 
the target antigens of pemphigus.134 Subsequently, Schaerer L, Trüeb RM in 
2003, first reported the positive DIF findings in the Outer root sheath of 
plucked hair in 100% of their patients and hence, suggested that hair DIF could 
be a suitable and non-invasive alternative to skin DIF.17 Similarly a study of 50 
patients with active pemphigus by Kumaresan, Rai R, et al in 2010,  also 
demonstrated 100% positivity of hair DIF.20 
 
 A study by Daneshpazhooh M et al. with 110 patients and Rao R et al. 
with 20 patients with active Pemphigus, showed positive DIF findings in 
90.9% and 85% of the patients, respectively.18,19 
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 Rao R et al in 2012, conducted a study to assess the role of hair DIF in 
monitoring the disease activity in pemphigus, they suggested that, in patients in 
clinical remission, DIF of hair could be an ideal substrate for assessment of 
immunological remission as it is simple and non- invasive.169 
 
 However, till date, there are only limited studies available, assessing the 
role of hair DIF in pemphigus patients in clinical remission. 
 
 With this background we conducted a study in our department with 30 
patients with Pemphigus Vulgaris, in clinical remission for atleast 6 months. 
All the patients in our study belonged to the mucocutaneous phenotype of 
Pemphigus and had a history of scalp involvement. The DIF of hair and skin 
was performed when the patient was at or more than 6 months of clinical 
remission.  
 
 The skin sample for our study was obtained from the upper trunk as a 
study showed that following oral mucosa, scalp and face the upper trunk is also 
rich in the target antigens of pemphigus. 
 In majority (30%) of our patients, the age of onset was between 31-40 
years, similar to other Indian studies.37,40,47 However, western studies 
have reported the common age of onset as 50-60 years.48 
 A study by Mascarenhas MF et al in Goa and Kanwar et al in North 
India showed a female preponderance.37,38 
Similarly, our study also showed a female preponderance with a male-                   
female ratio of 1:1.7 
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 In our study, 100% of our patients had positive DIF findings during the 
active stage of the disease, similar to the study by Schaerer & Trueb and 
Kumaresan, Rai R et al.17,20 
 
 To our knowledge,  apart from the study published by Rao et al. 
assessing the role of hair DIF in monitoring disease activity in pemphigus, 
there is only one study by Daneshpazhooh M et al. with 55 pemphigus patients 
in clinical remission for assessing the role of hair DIF in pemphigus patients in 
clinical Remission.170 
 
 In their study, the mean duration of disease was 69 months, whereas, in 
our study it was only 45 months. 
 In their study, the duration of remission was 12-24 months in majority 
of their patients(32/55), whereas, in our study majority(24/30) of the  
patients were in clinical remission only for a period of 6-12 months, 
which was significantly lower. 
 The sensitivity of hair DIF in their study was 79%, which is similar to 
our study with a sensitivity of 80 %. 
 The specificity of hair DIF  in their study was 48 % and in our study it 
was 70 %, which was significantly higher.  
 The positive predictive value of hair DIF in their study was 61% and in 
our study it was 57.14 %. The positive predictive value refers to the 
probability that the patients with positive results, truly have the disease. 
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 The negative predictive value of hair DIF in their study was 68 % 
whereas in our it was 87.5%, which was significantly higher.  
Negative predictive value is the probability that patients with a negative 
results, truly don't have the disease.  
 
 In our study, a total of 18 patients were on treatment. In these patients, 
the hair and skin DIF negativity was higher. In the remaining 12 patients, who 
were not on treatment, the positivity of hair DIF was higher than skin DIF. 
However, both the findings were not statistically significant. 
 
 In our study, 14 patients with negative skin and hair DIF, had a longer 
duration of disease and 8 patients with positive skin and hair DIF, had a shorter 
duration of remission. These findings were not statistically significant.  
 
 Interestingly, in our study we noted that the female patients had a longer 
duration of remission when compared to the males, which was statistically 
significant. However, it should be emphasized that our study had a female 
predominance and also the duration of disease among patients was widely 
variable. 
 
 We also noted that 50% of patients treated with steroids and 
azathioprine had both skin and hair DIF negative, whereas only 33% of patients 
treated with steroids and cyclophosphamide had both skin and hair DIF 
negative.  
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 Even though skin or mucosal DIF is considered as the ideal substrate for 
assessment of immunological remission, we would like to highlight the fact 
that 6 patients in our study  had  positive hair DIF even though skin DIF was 
negative. Thus, indicating that these patients were not yet in immunological 
remission. Had the clinician relied only on the DIF of skin for the assessment 
of the immunological status to aid his decision, this finding could have been 
missed and the patient’s treatment would have been discontinued prematurely.   
Hence, we suggest that DIF of hair can be done in patients with negative skin 
DIF, before declaring that the patient is in clinical and immunological 
remission and stopping the treatment. Alternatively, in patients in clinical 
remission, DIF of hair can be done at frequent intervals and when it becomes 
negative, DIF of skin could be done for confirmation and then the treatment 
can be discontinued. 
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CONCLUSION 
 
 
  Our study was done to assess the role of hair DIF in assessment of 
immunological remission in pemphigus . The sensitivity of hair DIF in our 
study was not high enough to suggest that it could replace the use of skin or 
mucosal DIF for assessment of immunological remission. However, one cannot 
disregard the positivity of hair DIF in the setting of skin DIF being negative as 
shown in our study. Hence, DIF of hair is a simple, non invasive & cost 
effective procedure and can be used as an additional procedure for assessment 
of immunological remission in Pemphigus Vulgaris. 
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INTRODUCTION 
 Pemphigus is a chronic autoimmune blistering disorder of the skin and 
mucosa. The word pemphigus, is derived from the greek word “pemphix” 
meaning  a bubble or blister. It is characterized by  the development of flaccid 
intraepidermal bullae, erosions and ulcerations over the skin and/ or mucosa 
with  antibodies directed against desmogleins 1 and 3.1  Direct 
immunofluorescence of peri-lesional skin or mucosa showing intercellular 
space (ICS) deposition of IgG  and/or C3 is considered as the gold standard in 
the diagnosis of pemphigus.    
 Systemic steroids alone or in combination with other 
immunosuppressives are the mainstay of treatment and long-term 
administration of the same is associated with significant adverse effects, 
morbidity and mortality.  It has been shown that upto 77% of deaths in 
pemphigus was related to high dose corticosteroids.2 
 
 Therefore, a system is required to monitor disease activity so as to lower 
the dosage of the drugs and eventually withdraw treatment. The main aim of 
treatment in pemphigus is to attain clinical and immunological remission. 
Hence, the most challenging decision we face in the management of this 
disease is the decision regarding when to stop the treatment. Various methods 
for assessment of immunological remission include: direct 
immunofluorescence, indirect immunofluorescence and anti-desmoglein 
ELISA titres, of which IIF is commonly used.3-8 However, indirect 
immunofluorescence titres do not always correlate with the disease activity.9-12 
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 It has been shown that negative direct immunofluorescence  of skin or 
mucosa is considered as a good indicator of immunological remission.13-16 But, 
it is an invasive and expensive procedure and the patient may not be willing for 
the same.  
 Recently, pemphigus-specific immunofluorescence pattern has been 
demonstrated in the outer root sheath of hair follicles which is structurally 
similar to the epidermal keratinocytes, with a sensitivity ranging from 85-
100%.17-20 
  Hence, DIF of hair may be an ideal substrate for assessment of 
immunological remission as it is a simple, non- invasive and a cost effective 
procedure.  
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AIM 
 
 Comparison of  direct Immunofluorescence of plucked hair and skin for 
evaluation of immunological remission in pemphigus. 
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REVIEW OF LITERATURE 
 
 
HISTORY 
  
 
 Pemphigus was probably first described by McBride in the year 1777 
and Wichmann in 1791. Wichmann applied the term “pemphigus” to his 
patients who had flaccid bullae and painful oral ulcers.21 
 
 In 1844 -  Cazenave first described pemphigus foliaceus as a  
superficial, rapidly spreading form of pemphigus.22,23  
 
           In 1868, Ferdinand von Hebra stated  that pemphigus was a chronic 
disease and was the first to coin the term pemphigus vulgaris.21.24 
 
  In 1886, Neumann described a disease with “warty granulations” as 
pemphigus vegetans.21,22,24 
 
In 1881- disruption of epidermal cells in patients with pemphigus, was 
first described by Auspitz. 25,26 
 
            In 1926, Senear and Usher described pemphigus erythematosus.  
 
In 1943, Civatte delineated acantholysis as histopathologic hallmark in 
pemphigus.  He described acantholysis and intraepithelial bulla formation in 
pemphigus vulgaris, pemphigus foliaceus and pemphigus vegetans. These 
findings  distinguished  pemphigus from other blistering disorder of the skin.28 
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In 1953, Walter Levers distinguished pemphigus vulgaris and 
pemphigoid bullosus, by both clinical and histological parameters. He 
described  pemphigus vulgaris as a life-threatening disease, characterized by 
intra-epidermal blisters and acantholysis with usually a lethal outcome,.29 
 
 In 1964, Beutner and Jordon using indirect immunofluorescence 
demonstrated auto-antibodies on the cell surface of keratinocytes.30 
 
 In 1976- Schiltz and Michel demonstrated that autoantibodies in 
pemphigus cause the blister formation by human skin organ culture.31 
 
 In 1982, Anhalt et al demonstrated the same using passive transfer of 
antibodies to neonatal mice.32 
 
 In 1980s, pemphigus target antigens were identified by 
immunoprecipitation and immunoblotting methods.33,34 
 
 In the early 1990s, isolation of cDNA for pemphigus antigens revealed 
the desmogleins as the target antigens in pemphigus.35,36 
 
 
EPIDEMIOLOGY 
 
IN INDIA 
 
The incidence of pemphigus in India, among the out-patient attendees 
ranges  from 0.09%- 1.8%. 37,38 
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Study conducted in Thrissur Kerala, has shown the incidence of 
pemphigus to be 4.4 per million population/year.39 
 
Pemphigus Vulgaris was the most commonest accounting for about           
75-96% of the total Pemphigus patients.38,40 
 
A review article by Sehgal et al, showed that P.V was the most 
commonest followed pemphigus foliaceous, pemphigus erythematosus, 
pemphigus Vegetans in decreasing order of frequency.40 
 
Incidence of pemphigus is more common in Ashkenazi jews, Japanese 
and Indians.40,41 
 
 
WORLD WIDE 
 
 
 P.V prevalence ranges from 0.18 to 6.96 case per million population.42,43 
 
 A study showed that, the proportion of PV and PF was almost equal in 
patients from UK, while PV was the predominant type in Indian 
patients.44  
 In Tunisia- incidence is about 2.5 cases per million population/ year.45 
 
 In france- incidence is 1.3 cases per million population/year. 45 
 
 In finland- prevalence is  0.76 cases per million population.46 
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AGE 
 
In India, P.V seems to affect the younger age group, in the 3rd to 4th 
decade.37,40,47  This is in contrast to the western countries, where the common  
age of onset was 50-60 years.48 
  
 
GENDER 
 
 
Both males and female are equally affected. Although,  in few studies 
the gender predisposition has contrasting results.49 
 
RACE 
 
More common in Ashkenazi Jews and Mediterranean population.48 
 
 
 
GENETIC FACTORS 
 
 
Pemphigus belongs to a group of polygenic disorder.  
 
 
 The higher incidence of pemphigus vulgaris and the earlier age of onset 
of pemphigus seen in India have been linked to higher frequency of  
DSG3*TCCCC halotype in Indian patients.50 
 
HLA DRB1 *0402, 1401/04, HLA DQB1 * 0503 has been associated   
with increased susceptibility to PV, HLA DRB1 *04 associated with P.F (both 
sporadic and endemic form) and HLA DRB1 *0102, 0404 & 1402/06 
associated with endemic P.F.51-54 
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These evidence suggests that genetic factors are probably involved in the 
disease. 
An inherited predisposition is further supported by the following evidence: 
 
a. Difference in clinical profile of Pemphigus between different ethnic 
groups. 
b. Ashkenazi Jews are more commonly affected. 
 
c. PV occurring in South African Indians is similar to that occurring in 
their origin country.55 
d. 40-60% of 1st degree relatives of patients with P.V have shown 
circulating anti- desmoglein antibodies. 52,56  
e. The first-degree relatives of patients with pemphigus have an increased 
prevalence of auto-immune diseases.57 
f. Familial cases have been reported.58 
 
 
 
DISEASE ASSOCIATIONS 
 
Pemphigus has been associated with SLE, Myasthenia gravis, thymoma,  
lymphoproliferative diseases.59,60  
  
 Herpes simplex, EB virus, HHV 6 and 8 DNA have been detected in 
skin or  mononuclear cells of  pemphigus patients 61,62 and there are reports of 
patients with pemphigus and coexisting HIV infection.63
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  A study on Iranian PV patients showed a positive correlation with oral 
contraceptive use and pesticide exposure.64 
 
PATHOGENESIS 
 
The hallmark of pemphigus is the presence of IgG auto-antibodies 
directed against desmoglein 3 and/or 1. These antibodies play an important role 
in the loss of keratinocyte cell to cell adhesion and subsequent blister 
formation. 
 
DESMOSOMES AND DESMOGLEINS 
 
Adhesion of keratinocytes is mainly by the cadherins. These cadherins 
are calcium dependant transmembrane glycoproteins, localized in two adhesion 
junctions, the desmosomes and the adherens junctions. The Desmosomes are 
the electron-dense structures that are responsible for anchoring the intermediate 
filament within the keratinocytes to the plasma membrane and adjacent cells.65   
. 
 The  components of desmosomes are: the desmosomal cadherins 
(desmogleins and desmocollins), the armadillo  proteins (plakoglobin, 
plakophilin) and the plakins (desmoplakin, etc) of which desmogleins and 
desmocollins are the major components.66 
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COMPONENTS OF A DESMOSOME65 
 
Figure - 1 
dp- desmoplakin, Dsg- Desmoglein, pkp- Desmoplakin, dsc- Desmocollins, 
kf- keratin intermediate filaments, dg- Desmoglea, odp- Outer dense plaque, 
idp- Inner Dense Plaque, pm- Plasma Membrane, dm- Dense midline. 
 
 
 
 In the desmosomes, cadherins are the transmembrane components and 
plakoglobin, plakophilin, and desmoplakin are the cytoplasmic components. 66 
 
 The desmoplakins form the major part of the inner dense plaque and its 
carboxy terminus binds to the keratin intermediate filaments and the amino 
terminus binds to the plakoglobin. Various domains in the plakoglobins in turn 
binds to the desmogleins and the desmocollins. The plakophilins binds to 
various desmosomal components and help in clustering and stabilizing them.67 
 
 
 
 
11 
 
 
STRUCTURE OF DESMOGLEINS:66 
 
 
 
 
 
Figure - 2 
 
 
 All the cadherins contain repeated amino acid sequences, called 
cadherin repeats, which have calcium-binding motifs in their extracellular 
domains. Like the classic cadherins, desmogleins have four cadherin repeats in 
their extracellular domain, but with an extra carboxy-terminal domain with 
repeats of 29 ± 1 aminoacid residues  in their intracellular domain. 66 
 
DISTRIBUTION OF DESMOGLEINS IN THE SKIN. 
 
 Desmogleins have four isoforms, Dsg 1 to 4.  Desmoglein 1 and 3 is 
expressed in the stratified squamous epithelia, while Dsg2 is expressed in all 
desmosome possessing tissues, predominantly in simple epithelia. Desmoglein 
4 is found in hair follicles and the granular layer.66 
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The expression of desmogleins in the skin varies based on the 
differentiation and also its expression pattern in mucosa differs from that in the 
skin. Desmoglein-3 expression is restricted to the basal and suprabasal layers of 
the epidermis, whereas desmoglein-1 is present in the entire thickness of the 
epidermis but more in the  differentiated cells, i.e, in the upper layers.68-70 
 
In mucosae, dsg-1 expression is weak, whereas, dsg-3 is strongly 
expressed throughout.69 
  
Pemphigus IgG antibody binds to the extracellular domain on the 
amino-terminal region of dsg-3.  Where it has a direct effect on the function of 
the desmogleins.72,73 
 
 The pathogenicity of Dsg antibodies depends on their titre and subclass. 
In patients with active disease, both IgG1 and IgG4 subclass antibodies are 
present, but the IgG4 is more specific and pathogeneic.74,75 
 
The pathogenicity of desmoglein antibodies is supported by,  
 
a) Studies showing a correlation between titre of antibody in patient’s 
serum and the disease activity. 76-78 
 
b)  transient bullae in the newborn may be caused by Transplacental 
transfer of maternal PV antibodies.79 
 
c) PV  IgG antibodies causes suprabasal  acantholysis in neonatal mouse 
model.80  
 
d) Prior absorption of antibodies of the pemphigus vulgaris prevents blister 
formation.81  
 
e) desmoglein-3 antibodies can induce acantholysis can in mice which can 
be enhanced by adding desmoglein-1 antibodies.82 
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DISTRIBUTION OF DESMOGLEINS IN THE HAIR 
 
Desmoglein 1 
 It’s expressed in the differentiated cells. In the inner root sheath and 
in the infundibulum of hair follicle its distribution is similar to that found in the 
epidermis.68 At the level of bulge its confined to the suprabasal layers and 
undetectable in the basal layer.68 Towards the base of the hair follicle dsg 1 
distribution gradually becomes confined to the inner most layers of the ORS 
and eventually disappears in the lowermost part of the hair follicle ORS.68 
Desmoglein 2 
 
 It’s highly expressed in the least differentiated cells such as the basal 
layers of the bulge region of hair follicle and bulb matrix.68   It’s also present in 
the basal cells of the ORS in the lower part of the hair follicle.68 
Desmoglein 3 
 
 Dsg 3 expression pattern correlated to the type of keratinisation. It is 
present in all the layers of outer root sheath, predominantly in the basal              
layers. 68   At the level of infundibulum its expressed predominantly in the basal 
layers.68   Its also expressed in the cyst walls in the areas of trichilemmal 
keratinisation, medulla of the hair shaft and in the suprabasal matrix and the 
precortical cells. 68   Dsg 3 also anchors the telogen hair to ORS of  the 
follicle.83 
Desmoglein 4 
 Dsg4 is expressed in the suprabasal epidermis and  the IRS , pre-cortex 
and the matrix.84 
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DISTRIBUTION OF DESMOGLEIN 1 & 3 IN THE HAIR 
FOLLICLE 
 
 
Figure - 3 
 
Table - 1 
DSG EXPRESSION IN HAIR FOLLICLE- SUMMARY68 
 
REGION DSG 1 DSG 2 DSG 3 
Basal cells of infundibulum +/- + ++ 
Infundibulum -suprabasal 
cells of  
+++ - + 
Isthmus - Suprabasal cells of 
ORS 
++++ + to - +++ to - 
Suprabasal cells of ORS from 
suprabulbar region to bulge.  
- To ++ ++ to - +++ to ++ 
Bulge region  - +++ + 
Basal cells of ORS below the 
bulge region 
- ++ to +++ +/- 
Precortical cells - + + 
Medulla + - +++ 
Inner Root Sheath +++ - - 
Matrix  - ++ +/- 
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DESMOGLEIN COMPENSATION THEORY85 
 
 
 
Figure - 4 
 
 The triangles represent the Desmoglein 1 and 3 distribution. 
 Green triangle- Dsg 1 & Red triangle- Dsg3. 
 A - skin and B - mucous membrane.  
 
A1- In pemphigus foliaceus antibodies are present only against dsg 1. 
Hence, blisters occur only in the superficial layers of the epidermis  as Dsg3 
functionally compensates for the impaired function of dsg 1 in the lower  
epidermis, 
 
A2- In mucosal dominant PV,  only anti-desmoglein 3 antibodies are 
present & hence, there’s  no or only limited bullae  in the skin as desmoglein 1 
compensates for the Dsg3 loss;  
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B2- However, in mucosal dominant PV erosions and bulla occur in the 
mucous membranes, as it has low levels of Desmoglein 1 and will not 
compensate for the Dsg 3 loss .  
 
A3, B3-When sera contain both anti-Dsg1 and anti-Dsg3 IgG, the 
function of both Dsgs is compromised and blisters occur in both the skin and 
mucous membranes. 
 
In neonatal skin, the situation is similar to that shown here for mucous 
membranes. 
 
Acantholysis is the basic patho- mechanism of pemphigus. However, the 
exact mechanism of disruption of adhesion between keratinocytes is not fully 
known.  
 
The following mechanisms have been proposed: 
 
1. STEARIC HINDRANCE 
Binding of the antibodies to the target antigen can cause disruption of 
it’s  adhesion function by stearic hindrance. 86 
 
2. BASAL CELL SHRINKAGE THEORY 
The PV antibodies induces phosphorylation of adhesion molecules and 
structural proteins leading to weakening of the intercellular junction and 
collapse of the cytoskeleton respectively.  This in-turn leads to cellular 
shrinkage and separation of the keratinocytes.87-89 
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3. APOPTOLYSIS HYPOTHESIS 
This theory links the suprabasal acantholysis and cell death pathway to  
basal cell shrinkage.90 
 
Binding of antibodies to keratinocyte 
Activation of signaling elements 
Elevation of intracellular calcium 
Activation of caspases 
Basal cell shrinkage causing acantholysis starts.( due to of cortical actin 
filaments reorganization and collapse and retraction of  tonofilaments, cleaved 
by caspases ) 
 
Acantholysis progresses due to Activated cell death enzymes causing  cleavage 
of  cellular proteins  leading to cell collapse, 
 
Desmosomes Tearing off from the cell membrane & thus stimulate production  
of secondary antibody. 
 
Rounding up and death of acantholytic cells ( in the lower compartment of 
epidermis  secondary to irreversible damage to nuclear and mitochondrial 
proteins). 
 
 
Thus, according to this theory same cell death enzymes, mediate both 
acantholysis and apoptosis of keratinocytes. 
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4. MULTIPLE HIT HYPOTHESIS 
 According to this hypothesis, apart from Dsg 1 and 3 antibodies other 
antibodies directed against desmosomal proteins like plakins, desmocollins  
and non desmosomal proteins like Acetylcholine α 9 receptors, phemphaxin, 
thyroperoxidase, annexins  are also involved in  the pathogenesis of 
Pemphigus. 91 
 
 
5. ROLE OF T CELLS  
 
It’s exact role in PV is not clear. But, autoreactive T- cell response to 
Dsg 3 may be critical in it pathogenesis.  These CD4 T cells produce Th2 
cytokines- Il-4 & Il-10. The Th2 dependant IgG4 subclass is predominant               
in active PV and Th1 dependant IgG 1 subclass is predominant during 
remission.92 
 
Recently, it has been demonstrated that a defect in the regulatory 
mechanism of Dsg 3 specific T cell leads to loss of tolerance of the B cells 
leading to autoantibody production.92 
 
 
DRUG INDUCED PEMPHIGUS 
 
Drugs causing pemphigus can be classified into 2  types 93 
a. Thiol/ SH group- penicillamine, captopril,piroxicam, etc 
b. Non thiol group- penicillin, ampicillin, amoxicillin, rifampicin, 
propanolol, phenytoin, phenobarbitone. 
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Among these penicillamine is the most commonest cause. 
Thiol group of drugs often induced Pemphigus, whereas the non thiol drugs 
trigger the disease in a predisposed individual.93 
 
NON DESMOGLEIN ANTIBODIES 
 
Autoantibodies to desmocollins have also been detected in few PV 
patients sera.94,95  
 
In a study, antibodies to e-cadherin has been detected, some but not all 
of which cross-react with desmoglein-1.96 
 
Apart from antibodies to cadherins antidesmoplakin  antibodies have 
been reported in severe pemphigus vulgaris.97  
 
 Antibodies to cholinergic receptors have been observed in pemphigus 
sera98 and cholinergic agonists has been shown to  inhibit acantholysis induced 
by pemphigus sera in vitro and have an apparent steroid-sparing effect in vivo 
in pemphigus.99  
 
 However, The significance of all the various antibodies in the 
pathogenesis of Pemphigus remain to be elucidated.100,101 
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CLASSIFICATION OF PEMPHIGUS 
 
1.   Pemphigus vulgaris 
 
      Variant: Pemphigus Vegetans 
 
2.  Pemphigus Foliaceous 
 
      Variants: Pemphigus Erythematosus 
                                     Pemphigus Herpetiformis 
 
3.   Induced pemphigus 
 
4  Intercellular IgA dermatosis 
 
5.  Paraneoplastic Pemphigus 
 
 
 
CLINICAL FEATURES 
 
Pemphigus vulgaris  can be divided in to two types102-  
 
• Mucosal dominant type:  with predominant mucosal erosions but 
minimal skin lesions;  
•  Mucocutaneous type:  mucosal involvement along with extensive bulla 
and erosions in skin. 
 
MUCOSAL INVOLVEMENT 
 
In  50 to 70% of patients have oral lesions are present.  It may precede 
the skin lesions by months or be the only manifestation of the disease.2,103,104 
 
Commonly, patients present with slow or non healing ill-defined 
erosions in the buccal or palatal mucosa with little or no surrounding 
inflammation. There is peripheral extension of the erosions with epithelial 
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shedding.105  In the oral cavity, intact bulla is rare. Other mucosa that can be 
involved are, the, oesophagus, nasal cavity, conjunctiva, pharynx, larynx, vulva 
cervix and urethra.106-111 
 
 Frequently superimposed candidial infection may be present.  
 
 
 
CUTANEOUS MANIFESTATION 
 
 Patients develop flaccid bullae with clear fluid over normal looking skin 
or an erythematous base. The content soon becomes turbid and ruptures to form 
erosions with peripheral extensions, which show little or no tendency to heal on 
its own. These erosions heal with hyperpigmentation.102 
 
 The skin lesions are predominantly seen over the axilla, groin, face, 
scalp, pressure bearing areas and trunk.102 
 
COMPLICATIONS 
 
Most common complication in pemphigus is secondary infection. If 
untreated it may even lead to sepsis and subsequently death.  
 
 The other complications are mainly related to the long-term treatment 
with steroids and other immunosuppressive agents. They include, adrenal axis 
suppression, cushingoid habitus, hypertension, fluid retention, osteoporosis, 
diabetes, cataracts, glaucoma, increased susceptibility to infections, and 
reactivation of tuberculosis. 
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PROGNOSIS OF PEMPHIGUS VULGARIS 
 The severity and natural history of pemphigus are variable. Advent of 
systemic steroids in the treatment of pemphigus has reduced the mortality to  
5% - 15%.2,113  The morbidity and mortality are related mainly to the disease 
severity, the prednisolone dosage required to induce remission, and some of 
these patients succumb to the complications of therapy and the presence of co-
morbidities.2,112,114–116.   Disease severity generally reduces with time and most 
relapses occur in the first 2 years.117  
 
Several prognostic factors have been identified for pemphigus, they include:118 
A. Type of pemphigus: PV and paraneoplatic pemphigus have the worst 
prognosis 
B. Age of the patient at disease onset: elderly patients have a poorer 
prognosis 
C. Race: The prognosis is worse in Jews.113 
D. Progression of disease prior to onset of treatment: patients with 
minimal disease activity for a longer time have better prognosis than 
those patients with rapid progression of the disease without 
treatment. 
E. Dosage of steroids required for disease control: patients who require 
higher dose of steroids with >180mg/day have a higher mortality 
rate. 
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F. Mucosal or skin involvement: those patients who initially have only 
cutaneous involvement than those with mucosal involvement have a 
better prognosis. 
G. Time of initiation of treatment: patient in whom steroids were started 
immediately, or within 6 months of onset of the disease had a better 
prognosis.  
 
SCORING SYSTEMS IN PEMPHIGUS 
 
 Due to the wide variation in the presentation of the disease, there is a 
need to devise certain objective parameters for evaluation of the disease 
progression or its response to therapy.  Hence, various scoring systems have 
been used, such as, Pemphigus Area and Activity Score, Pemphigus Activity 
score,  Pemphigus Disease Activity Index (PDAI), Autoimmune Bullous Skin 
Disorder Intensity Score(ABSIS), etc.119 
 
 Of all these scoring system PDAI score and ABSIS score are more 
commonly used. PDAI score combines mucosal and cutaneous disease in well-
defined anatomical location and also assesses the size and number of lesions, 
along with scoring for post-inflammatory hyperpigmentation.119 
 
 The main advantage of ABSIS score is that it is a quality- and quantity-
based score for oral mucosal and cutaneous lesions. This scoring system, 
monitors the clinical status of the patients over time.  
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 In addition, this system can be used for assessing other autoimmune 
bullous diseases, and thus is more versatile. 119 
 
PEMPHIGUS VEGETANS 
 It’s a variant of PV.  It’s of two types, the Neumann (severe) type and 
the Hallopeau (mild) type. The lesions are primarily seen in the flexures.  
 
 In Neumann type- initially vesicles and bullae develop which rupture to 
form hypertrophic granulating erosions, with easy bleeding. These lesions 
evolve into vegetating masses discharging pus and serum and the edges may be 
studded with small pustules.  New vegetative lesions may arise from erosions 
at the edge of the lesions, which eventually become fissured and 
hyperkeratotic. 
 
 In Hallopeau type- Pustules rather than vesicles are seen in the early 
lesions but they progress to vegetating plaques. 
 
SIGNS FOR PEMPHIGUS 
NIKOLSKY’S SIGN 
 Firm tangential pressure with a finger over a bony prominence will 
produce an erosion by separate normal looking epidermis from the dermis. It’s 
indicative of acantholysis. 
 Positive Nikolsky sign is indicator of active disease.120 
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BULLASPREAD SIGN/ LUTZ SIGN 
 Unidirectional pressure applied by a finger causes peripheral extension 
of the bulla beyond the marked margin.120  
 
ASBOE HANSENS 
 Pressure is applied to the centre of the bulla which causes peripheral 
extension beyond the marked margins.120 
 
INVESTIGATIONS 
1. TZANCK SMEAR 
 It is a useful bedside test for diagnosis of pemphigus.120  The intact roof 
of the blister is separated and the floor of the blister is scraped using a  scalpel. 
The material obtained, is then placed over a glass slide and tzanck smear is 
done with Giemsa stain. 
 
 The smear shows multiple acantholytic cells. It is a rounded keratinocyte 
with a hypertrophic nucleus and hazy or absent nucleoli, increased nuclear to 
cytoplamic ratio with peripheral condensation of the cytoplasm (mourning 
edged cell), causing a perinuclear halo.120   
 
 Other findings that can be detected in Tzanck smear include sertoli’s 
rosette and streptocytes. 
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 Sertoli’s rosette refers to a central keratinocyte surrounded by 
leucocytes. Streptocytes refers to arrangement of leucocytes in chains. 
 
 In PF the acantholytic cell is smaller, less rounded, or cuboidal shaped 
with a small nucleus and abundant cytoplasm. The cells may have 
keratohyaline granules and show keratinization. 
 
 
2. SKIN BIOPSY AND HISTOPATHOLOGY 
 Biopsy for H&E staining should be done from an early intact bulla or 
vesicle.   
  
 The earliest change in PV is may be rarely, eosinophilic spongiosis and 
most commonly spongiosis in the supra basal layers, which is considered as the 
earliest manifestation of acantholysis.121 
 
 This acantholysis initially leads to formation of cleft followed by bulla 
in the supra basal layers.121 
 
 In a well developed lesion, suprabasal bulla with acantholysis and 
acantholytic cells in the blister cavity is noted. Basal keratinocytes show the 
characteristic tomb-stone appearance. This is because basal keratinocytes show 
loss of  adhesion with adjacent keratinocytes but remains attached to the 
basement membrane. The intraepidermal acantholysis may sometimes involve 
the adnexal structures. 121 
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 There is little inflammatory infiltrate during the early stages of the 
blister, with superficial dermis showing perivascular lymphocytic infiltrate and 
dermal edema. However, if eosinophilic spongiosis is present in the early 
stages predominantly eosinophilic infiltrate is seen in the dermis. 121 
 Several changes occur in the late stages of the bulla. The dermis shows 
mixed inflammatory infiltrate of neutrophils, lymphocytes, eosinophils and 
macrophages. The bulla may rupture to form an erosion or an ulceration with 
the base showing acantholytic cells.121 
 Sometimes an older bulla may show several layers of epidermis at the 
base due to keratinocyte migration and proliferation.  Lastly, there may be 
down growth of the epidermis giving rise to villi.121  
 In case of an oral mucosal biopsy it’s difficult to demonstrate an intact 
bulla. Hence, only erosions and ulcerations of the mucosa is detected. And 
biopsy is taken from the edge of the erosion with intact adjacent mucosa in 
order to demonstrate the typical pathological findings.121 
 
Pemphigus Vegetans 
 Histopathology shows suprabasal cleft and the vegetating lesions show  
hyperkeratosis, papillomatosis and acanthosis. Some bulla may contain 
eosinophils and few acantholytic cells are present. In older lesions, eosinophilic 
abscesses may be present in the epidermis.  In the early pustular lesions of the 
Hallopeau type, eosinophilic spongiosis or microabscesses are common. With a 
heavy of lymphocytic and eosinophilic infiltrate with few neutrophils in the 
dermis.122 
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3. IMMUNOFLUORESCENCE 
 Immunofluorescence is a laboratory technique used for demonstration of 
the presence of tissue-bound and circulating antibodies.  Both direct and 
indirect immunofluorescence can be done for the diagnosis of pemphigus. 
Direct immunofluorescence of skin or mucosa for the detection of anti-
desmoglein 3 and / or 1 antibodies is considered as the gold standard in the 
diagnosis of pemphigus.   
 
The sample for direct immunofluorescence  is obtained from the 
perilesional skin or mucosa. 
 
History  
It was in the year 1941, that Coons et al first developed the 
immunofluorescence technique with a blue fluorescing compound, β 
anthracene, which made it possible to visualize the microscopic antigens, 
antibodies and other elements in tissue sections or cell smears.123 
 
 Diagnostic immunopathology in dermatology began in the year 1963, by 
the demonstration of complement and immunoglobulins deposition in the 
dermo-epidermal junction of skin - Lupus band test in SLE.124 
 
 In 1964, Beutner and Jordon demonstrated antibodies in the sera of 
pemphigus patients by indirect imunofluorescence.4 
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 In 1971, Jordon et al. demonstrated the deposition of IgG antibodies at 
the inter-cellular spaces in the epidermis by direct immunofluorescence of the 
lesional and perilesional skin.125  
 
Principle Of Fluorescence 
 Fluorescence is the light emitted by the singlet state of molecule on 
returning to its ground state, following absorption of photon from an external 
source. 
126
 
 
 
 
Figure -5 
A) Electron its in ground state in a molecule 
B) Electron excited by a high energy light- UV light and attains a higher 
energy state 
C) Electron unable to maintain its high energy state and drops to its lowest 
singlet energy state by losing energy as heat. 
D) The electron then spontaneous returns to its original ground state by 
emitting the remaining energy as light with longer wavelength and lesser 
energy in the form of fluorescence, 
ELECTRON 
B- INCIDENT UV  LIGHT C- HEAT LOSS D- FLUORESCENCE A- NORMAL  MOLECULE 
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BASIS OF IMMUNOFLUORESCENCE 
 
 In this technique, the antibodies, antigens or their complexes are stained 
with corresponding antibodies tagged with a fluorochrome and viewed under 
an fluorescent microscope with a mercury vapour or xenon light source and 
appropriate exciter and barrier filters.127 
 
 Fluorochromes are substances which can absorb light of a particular 
wavelength and attain an unstable higher energy state. Then on spontaneously 
returning to their original state, they re-emit light with longer wavelength.128 
 
Fluorochromes currently in use:128 
 Fluorescein Isothiocyanate (FITC) -  Produces apple green fluorescence 
 Tetramethyl Rhodamine isothiocyanate (TRITC) -  Produces red colour 
fluorescence 
 Phycoerythrin – Produces red fluorescence 
 
The FITC is linked with antibodies by a thiocarbamide linkage without 
interfering with their antigen binding capacity. 129 
 
TYPES OF IMMUNOFLUORESCENCE 
1. Direct Immunofluorescence 
2. Indirect Immunofluorescence 
3. Complement Indirect Immunofluorescence 
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1. Direct immunofluorescence  
 It’s a single step method, where the antibody specific to the target 
molecule is tagged with a fluorescent dye. 
 
 In case of auto-immune blistering disorders FITC tagged anti- 
immunoglobulin antibodies are used for the detection of in-vivo antibodies 
bound to the target antigen. For direct immunofluorescence sample is generally 
transported in michels medium where it can be stored for upto one month at  4 - 
8ºC.130,131   However, if sample is to be quick frozen immediately, it in can be 
transported in PBS medium. 
 
 
2. Indirect immunofluorescence 
 It’s a two step procedure, used to detect the circulating antibodies in the 
patients serum. In this procedure the antibody specific to the target molecule: 
the primary antibody is unlabeled, and a second anti-immunoglobulin antibody 
called the secondary antibody is directed toward the constant portion of the first 
antibody- is tagged with the fluorescent dye.130, 131 
 
 In case of autoimmune blistering disorder, First a substrate is incubated 
with the patients serum and then the FITC tagged anti-immunoglobulin 
antibodies are added for detection of the pathogenic antibodies.128 
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3. Complement Indirect immunofluorescence  
  
 This is another type of IIF. It’s a 3 step technique, in which the patients 
serum is incubated with the substrate, then  complement is added.  Fluorescein 
labelled anti-complement antibodies are then added to detect the presence of 
complement in the tissue. This test is done to detect complement fixing 
antibodies.132 
  
 The practical use of this technique is mainly limited to the diagnosis of 
Pemphigoid Gestationis. 132 
 
DIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
 
 Direct immunofluorescence is considered as gold standard in the 
diagnosis of pemphigus with a sensitivity of 95-100% 132,133 
 
 DIF shows deposition of IgG and/ or C3 against desmoglein 3 and / or 1 
in the epidermal intercellular spaces. This is described as ‘lace-like’ or 
‘chicken-wire’ or ‘fishnet’ pattern. In late lesions when the acantolytic cells are 
well developed the classical ‘fish-net’ pattern of immunofluorescence may 
become dot-like, corresponding to the  aggregation of desmosomes on the cell 
surface.133 
 
 The DIF staining shows IgG antibodies in 100 % of positive cases and 
C3 in 50-100%. 132  IgA and IgM may be present, but less frequently.102 
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 In Patients with active P.V, both IgG1 and IgG4 subclasses of antibodies 
are seen, but the IgG4 is pathogenic.74,75 
 
 The intensity of DIF staining correlates with the disease activity. 
However, in few patients it may be positive even when the patient is in clinical 
remission.132 
 
 In pemphigus vulgaris patients, negative DIF may be an indicator of 
immunological remission. And repeated negative DIF during clinical remission 
may be considered as a possible sign for apparent cure of the disease, and 
treatment may be discontinued in such group of patients.13-16  
 
False positive DIF 
 It is very rare, but non-specific intercellular staining can be seen in 
psoriasis, spongiotic dermatitis, bullous impetigo, and epidermis adjacent to 
ulcers secondary to any cause may have squamous intercellular substance IgG 
as the intercellular space may contain serum. 133 
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DIRECT IMMUNOFLUORESCENCE OF HAIR 
 
 The scalp is a commonly involved site in Pemphigus. Wilson et al, 
demonstrated that, in the scalp, the outer root sheath hair follicle and the 
dermal bulb matrix cells is rich in the target antigens of pemphigus. This may 
be the reason for scalp involvement in pemphigus.134 
 
 Recently, it has been shown that outer rooth sheath of hair follicle which 
is structurally similar to the epidermal keratinocytes also shows positive direct 
immunofluorescence findings with a sensitivity of 85-100%.17-20 
 
 Schaerer and Trueb in the year 2003, for the first time, demonstrated 
pemphigus specific DIF pattern in the ORS of the hair follicle of the plucked 
hair. They demonstrated positive DIF findings in 100% of their patients.17 
 
 Similarly another study demonstrated acantholysis in the hair follicle 
and also immune deposits specific to Pemphigus in the outer root sheath and 
matrix of hair follicle in the biopsy specimens.134 
 
 Another study on 50 patients with Pemphigus, characteristic DIF 
findings were seen in the outer root sheath of both telogen and anagen hair 
follicle in 100 % of patients irrespective of scalp involvement, they also 
demonstrated that  positive DIF findings were also seen in the body hairs.20 
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INDIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
 
 In this method circulating IgG antibodies are demonstrated in 80-90% of 
pemphigus cases.133   The substrates commonly used for IIF include guinea pig 
oesophagus, monkey oesophagus and normal human skin. Of which money 
oesophagus is considered as the ideal substrate.133 
  
 IIF has been widely used for monitoring of the serological activity of 
pemphigus patients. It has been demonstrated that the antibody titres in the 
patients sera in many instances, correlates with the disease severity.4-8 
However, other studies analyzing the serial titers by IIF, showed that the 
antibody titers do not always correlate with disease severity and hence, cannot 
be used as a guide to prognosis or monitoring the disease activity.8-12 
 
 Judd and Lever found that administration of a high dose of daily steroids 
resulted in clinical improvement as well as showed a marked fall in the titer of 
circulating antibodies. However, there was no predictable correlation between 
the disease activity and antibody titer by IIF when the patients were not 
receiving a high dose of steroids.10 
 
False positive IIF 
 False positive immunofluorescence staining can be seen in burns, 
penicillin allergy, toxic epidermal necrolysis, bullous pemphigoid, myasthenia 
gravis, SLE, lichen planus, cicatricial pemphigoid and in patients with 
antibodies against blood group A and B.133  
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ADVANTAGES  IMMUNOFLUORESCENCE 
 
1. Its used for laboratory diagnosis of various dermatological disorders. 
2. Various auto immune disorders with similar clinical picture are 
classified using immunofluorescence. 
3. Confirmation of diagnosis in cases where the clinical picture is atypical 
or non specific. 
4. Circulating antibody level detected by IIF can be used as a prognostic 
marker and also as a marker of disease activity and response to 
treatment in patients diagnosed with pemphigus. 
5. Antigen mapping can be done, which play an important role in 
classification of various form of hereditary epidermolysis bullosa. 
 
 
DISADVANTAGES OF IMMUNOFLUORESCENCE  
 
1. Expensive procedure and requires a lab with cryostat for frozen sections 
and a deep freezer for the storage of these specimens, with a well trained 
technician and  a pathologist proficient in the performance and 
interpretation of the results of immunofluorescence.  
2.  DIF stained slides cannot be stored for long-term, as the fluorescent 
stained slides quenches rapidly on exposure to sun light. 
3. False positive DIF and IIF can occur. 
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LIMITATIONS OF IMMUNOFLUORESCENCE TECHNIQUES 
 
1. Photobleaching 
It refers to the photochemical reaction which causes reactive oxygen species 
mediated destruction of a fluorochrome in the specimen. It can be reduced  by 
decreasing intensity and duration of excitation light, using a low concentration 
of a fluorochrome and addition of singlet oxygen scavengers. 
 
2. Autofluorescence 
 It is due to flavin coenzymes and reduced pyridine nucleotides. Fixation 
with aldehydes, particularly glutaraldehyde, can increase autofluorescence. 
 
3. Fluorescence Overlap 
 The emission signals may sometimes over lap if more than one colour 
fluorescence is emitted. 
 
ANTI-DESMOGLEIN ELISA TITRES 
  Recently, a sensitive and specific ELISA assay with recombinant dsg 1 
and dsg 3 for serodiagnosis of pemphigus has been used. Anti-desmogleins 
ELISA assay has shown that 95% of PV patients have desmoglein-3 antibodies 
and around 50% have desmoglein-1 antibodies. It has been shown recently that 
in appropriate dilutions, antidesmoglein-1 ELISA assays can also be used to 
monitor disease activity.3 
 
38 
 
 Many studies have demonstrated that anti-desmoglein ELISA titres has a 
better correlation with disease activity than IIF.138 
  
OTHER INVESTIGATIONS 
 
 Apart from these diagnostic investigations in pemphigus, various 
baseline investigations such as a complete blood count, Urine routine, Liver 
function Test, Renal function test Fasting and post prandial blood sugar, chest 
X Ray, Mantoux test are done to rule out secondary infection, pulmonary 
tuberculosis and other co- morbidities prior to starting the treatment. 
 
 
TREATMENT OF PEMPHIGUS 
 
 Pemphigus vulgaris if untreated is a fatal disease with mortality as high 
as 75% in the pre corticosteroid era.139 
 
 Currently, systemic corticosteroids with or without adjuvant 
immunosuppressive agents are considered as the first-line treatment of 
pemphigus. 
 
Objectives of treatment: 
 
a) Healing of the cutaneous and mucosal erosions.  
b) To prevent or decrease the  recurrences; 
c) To  improve the patients quality of life; 
d) Maintenance of remission with the least dosage of steroids or other 
immunosuppressives, in order to limit adverse effects of treatment. 
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 First step in the management of pemphigus, is assessing the patients 
general condition,  extent and severity of the disease and also presence of 
secondary infection and fluid and electrolyte imbalances. 
 
Followed by supportive care. This includes. 
1. Proper nursing care: Regular cleaning and dressing without extensive 
desloughing of the erosions until re-e pithelisation. This can be done by 
dressings with sterile petrolatum/ antibiotic gauze.  Measures should be 
taken for prevention of bed sores. And finally maintenance of proper 
oral hygiene. 
 
2.  Nutrition: patient requires a soft, high protein and calorie diet as there 
may be loss of proteins and also patient may be unable to eat due to 
severe oral ulcerations. If patient is not able to take oral feeds patient 
may require a feeding tube or parenteral nutrition. 
 
3. Control of secondary infection:  And if necessary antibiotics and anti 
fungal need to be added. 
 
4. Correction of fluid and electrolyte imbalances: Patient may also have 
significant fluid and electrolyte imbalances due to extensive erosions 
and in such conditions IV fluids should be administered.  
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SYSTEMIC CORTICOSTEROIDS 
 Corticosteroids are the first line treatment for pemphigus. 
 
 Prednisolone is the most widely used and therefore the preferred drug. 
Other steroids such as methylprednisolone, deflazacort, dexamethasone and 
betamethasone have also been used.  
 
 The optimum dosing schedule of corticosteroid is not known and the 
dosing is largely based on various studies.   
 
 For mild to moderate disease steroids are usually started at a dose of 60-
80mg/day and for a severe disease 80- 120mg/day.140 If there’s no clinical 
improvement in 1 week then the dose can be escalated every 4-7 days until the 
disease is under control. Once 80-90 % of the lesions have healed, the dose can 
be tapered by 50% every 2 weeks and maintain the patient on the minimal dose 
of steroid required for maintenance of clinical remission.141 
 
 On an average, appearance of new lesions stops within 2–3 weeks of 
starting treatment and full healing takes 6–8 weeks.142-45 
 
 Although corticosteroids cause rapid resolution of the lesions it cannot 
be administered in high doses on long term due to its significant adverse 
effects. One study had shown that upto 77% of the deaths in pemphigus was 
related to corticosteroids.2 Hence, adjuvant immunosuppressives are added in 
order to reduce the dose of CS required and also its related side effects.  
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Table - 2 
ADVERSE EFFECTS OF LONG TERM STEROIDS146 
CATEGORY ADVERSE EFFECTS 
Cutaneous Steroid induced acne, rosacea, increased 
susceptibility to cutaneous infections, 
delayed wound healing, striae, telogen 
effluvium, hirsutism, fat atrophy 
Glucocorticoid effects Hyperglycemia, increased appetite and 
weight gain 
Mineralocorticoid effects 
(due to sodium retention and 
potassium loss) 
Hypertension, congestive heart failure, 
arrhythmias secondary to hypokalemia, 
weight gain 
Lipid effects Hypertriglyceridemia, cushingoid habitus, 
menstrual irregularity 
Bone  Osteoporosis, osteonecrosis, indirect 
hypocalcemia 
Gastrointestinal  Peptic ulcer disease, bowel perforation, fatty 
liver, esophageal reflux, nausea, vomiting 
Ocular  Cataract, glaucoma, infection especially 
staphylococcus 
Psychiatric  Psychosis, agitation, personality changes, 
depression 
Muscular  Myopathy  
Neurologic  Pseudotumor cerebri, epidural lipomatosis, 
peripheral neuropathy 
Infections  TB reactivation, oppurtunistics infections 
like deep fungal, etc.  
Pediatric  Growth impairement  
Pulse therapy  Immediate flushing of face, hiccups, muscle 
weakness, asthenia,electrolyte shifts, cardiac 
dysarrythmias, seizures. 
The long term side effects are similar to 
daily steroid administration. Though its 
comparatively lower with pulse therapy   
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DEXAMETHASONE CYCLOPHOSPHAMIDE THERAPY 
 In order to overcome the side effects of long term steroids, pulse therapy 
was used. 
 
 Pulse therapy with steroids refers to administration of 
suprapharmacological dose of steroids as a bolus dose over a short period of 
time and then completely withdrawing it until the next dose.  
 
 Parischa et al in the year 1982 first proposed the Dexamethasone and 
cyclophosphamide pulse therapy for pemphigus.147 
 
ADVANTAGES OF DCP THERAPY 
• It induced faster clearance of lesions,  
• faster disease control, 
• lower cumulative dose of CS required and reduced side effects of 
corticosteroid therapy.  
 
DCP regimen has 3 phases: 147 
Phase - I 
 Dexamethasone  100mg in 500ml of 5% dextrose over 3 hours for 3 
consecutive days and Cyclophosphamide 500mg in 500ml of % dextrose on 
day 2 with daily 50mg cyclophosphamide. The same cycle is repeated every 28 
days until the patient is in clinical remission.  Oral Steroids may be added if 
disease is not under control.  
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Phase - II 
 DCP pulse therapy with daily oral CYP is continued for 9 months after 
clinical remission. 
 
Phase - III 
 DCP pulse therapy is stopped and daily oral Cyclophasphomide is 
continued 
 
Phase - IV 
 After stopping treatment the patient is followed up for a period of 10 
years for recurrences.  
 
ADJUVANT IMMUNOSUPRESSIVES 
 The two, first line adjuvant immunosuppressives are cyclophosphamide 
and azathioprine. Others include, mycophenolate mofetil, cyclosporine, 
dapsone, methotrexate 
 
CYCLOPHOSPHAMIDE 
 
   Cyclophosphamide has been used as an adjuvant to CS and is usually 
given at a dose of 1-3 mg/kg body weight. 
 
 Monthly IV cyclophosphamide in DCP pulse therapy with daily oral 
Cyclophosphamide in low doses has been used with success.152,154,155 
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 Various studies have shown that treatment with steroids and CYP as 
adjuvant showed better results than with steroid alone.147-149,154 
 
 However,  it should be used with caution in women of child bearing age 
and in patients who have not yet completed their family, as it’s known to cause 
secondary infertility due to amenorrhoea and azospermia, on long-term 
administration.151 
  
 A study has shown that remission in pemphigus can be maintained with 
low dose of Cyclophosphamide alone.152 
  
 Hence, according to BAD guidelines cyclophosphamide can be used as 
an alternative to Azathioprine.  
 
AZATHIOPRINE 
 It’s usually given at a dose of 1-3m g/kg/ day. However, ideally 
azathioprine dose should be tailored according to the TPMT levels. 
  
 The therapeutic effect of azathioprine is often seen only after 3-5 weeks.  
According to BAD guidelines, azathioprine is considered as the drug of choice 
for adjuvant therapy.  
  
 In terms of mortality and remission, Prednisolone with azathioprine   is 
more effective than Prednisolone alone. 147,153,154 
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MYCOPHENOLATE MOFETIL 
 
 MMF is usually given at a dose of 2-2.5g/day as a steroid sparing agent. 
One randomized controlled trial found MMF to be a less effective than 
azathioprine as a steroid sparing agent156, while another smaller trial found no 
difference in efficacy between the two.2 
 
METHOTREXATE 
 
 It can be considered as an adjuvant, if the more commonly used steroids 
sparing agents cannot be used for the patient. Earlier studies with high dose 
methotrexate showed high mortality rate.148  However, a recent study has 
shown that methotrexate can be useful and well tolerated in pemphigus patients 
with a considerable steroid sparing effect.158  And another study with 2  
recalcitrant cases of pemphigus showed good response with dexamethasone 
pulse therapy and methotrexate as an adjuvant.159 
 
CYCLOSPORIN 
 Initial there were case reports that cyclosporine was a useful adjuvant 
with  considerable steroid-sparing effects in PV.160-162   However, a recent trial 
has found that cyclosporine as an adjuvant therapy has no benefit over steroids 
alone.163 
  
46 
 
 Hence, according to BAD guidelines it is not recommended as an 
adjuvant in pemphigus. 
 
DAPSONE 
 Dapsone at a dose of 100-200mg/ day has been tried as an adjuvant in 
pemphigus.157  It has been found to be effective as a steroid sparing agent in 
few studies.164 
 
TETRACYCLINES AND NICOTINAMIDE 
 A combination of tetracycline 2g/day and nicotinamide1.5g/day has 
been shown to control the disease in 2 of 6 patients with PV. Minocycline and 
tetracycline has also been used as an adjuvant with steroids. 157 
 
RITUXIMAB 
 It is a chimeric monoclonal anti CD 20 antibody. Its effect, is mainly on 
the B cells.  
 Two studies, have provided valuable data regarding the safety and 
efficacy of rituximab. A study conducted by cianchini et al , showed that 86 % 
of patients treated with Rituximab achieved clinical remission and discontinued 
steroid within 6 months.167 And a study by Reguiai et al with 13 Pemphigus 
patients treated with Rituximab achieved clinical remission within the first 3 
months.166  
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Rituximab can be administered by two different protocol:166 
 The lymphoma protocol- 375mg/m2 BSA IV weekly for 4 weeks. 
 The rheumatoid arthritis protocol-  1g IV at an interval of 15 days. 
 
 However, the major concern for rituximab is its adverse effects such as 
neutropenia, increased susceptibility to infections, sepsis, DVT. 
 
IVIG 
 IVIG at a dose of 2g/kg body weight divided over 3 days has been tried, 
this cycle is repeated every 4 weeks.157 A study showed that a minimum of 3 
cycles of IVIG produced beneficial effects in 81% of patients with refractory 
pemphigus. Cost is the major limiting factor. 
 
 Other treatment options that have been tried in the Pemphigus include 
Gold, pyridostigmine bromide (a cholinergic agonist), biological such as 
infliximab and etanercept and procedures such as plasmapheresis, 
immunoadsorption and extracorporeal photopheresis.157 
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MATERIALS AND METHODS 
 
 
 It’s a hospital - based prospective study. 
 
 The study was done with patients diagnosed as a case of pemphigus 
vulgaris, attending the outpatient clinic in the Department Of 
Dermatology, Venereology, Leprosy, PSG IMS & R, Coimbatore. 
 
 The study was conducted over period of one year after obtaining 
institutional ethics committee approval was obtained prior to the 
commencement of the study. 
 
 Informed and written consent was obtained from all the patients and 
from the histopathology department, PSG IMS & R, where the 
investigations were done. 
 
 The patients were then tested for direct immunofluorescence of skin and 
Hair. 
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INCLUSION CRITERIA 
• Patients  with Pemphigus Vulgaris who showed intercellular deposition of 
IgG antibodies against Dsg3 and/or  Dsg1 and/or C3  in DIF of  skin and 
hair during the active stage of disease were included in the study 
• The patients had no new or non-healing skin or mucosal lesions in the past 
6 months or more. 
• And were On Daily prednisolone dosage equal to or less than 10mg 
• And/or adjuvant immunosuppressive therapy like azathioprine 50mg or 
cyclophosphamide 50mg. 
 
EXCLUSION CRITERIA 
• Patients with new or non healing skin or mucosal lesions in the preceding 6 
months 
• Patients with other bullous disorders. 
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Table - 3 
METHODOLOGY FLOWCHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 patients with pemphigus vulgaris in clinical remission for 6 
months or more were included in the study 
 
Informed and written consent was obtained 
History and physical examination was done 
Data was recorded in the datasheet 
Skin sample was obtained from the patients upper trunk 
hair sample was obtained in the same way as for a trichogram 
The distal end of the hair shaft with the bulb and outer rooth sheath 
is cut to about 2 cm. 
 
The shortened anagen hair type was further confirmed by 
microscopy 
 
Skin and hair sample is transported immediately in the PBS medium 
to histopathology lab and subjected to  direct immunofluorescence 
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1. METHOD OF DIRECT IMMUNOFLUORESCENCE OF SKIN 
 
1. A punch Biopsy specimen from the skin is received in the PBS medium 
2. Specimen is then snap frozen in the cryostat 
3. 5 frozen sections of 5µm thickness each is cut using a cryotome and 
placed on the slide 
4. Fan dry the section for 10 minutes 
5. The section is then washed in PBS at 7.4 pH for 10 minutes 
6. Fan dry the section for 10 mins 
7. Each of the slide is then incubated in room temperature for 1 hour with 
one of the following FITC-labeled antisera - IgG & Fibrinogen each 
diluted 1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS (The 
PBS used in the above steps contains Propidium iodide which is a 
Counter-stain ) 
8. Wash the slides 3 times with PBS for 10 minutes each 
9. Fan dry the sections 
10. Mount in buffered glycerol 
11. Examine under fluorescent microscope. 
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2. METHOD FOR DIF OF HAIR 
1. The hair sample is received in PBS medium to the histopathology lab. 
2. Hair sample is placed over a Glass slide 
3. Washed three times with PBS medium for 10 minutes each 
4. Then the specimen is fan dried 
5. Each of the slide is then incubated in room temperature for 1 hour with 
one of the following FITC-labeled antisera - IgG & Fibrinogen each 
diluted 1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS 
(The PBS used in the above step contains Propidium iodide which is a 
Counter-stain) 
6. Wash the slides 3 times with PBS for 10 minutes each 
7. Fan dry the sections 
8. Mount in buffered glycerol 
9. Examine under fluorescent microscope. 
 
 Based on the presence or absence of immunofluorescence deposits in the 
specimen the results were interpreted as positive or negative. 
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RESULTS 
 
Table - 4 
ATIENTS CHARACTERISTICS 
 
 
 
 
 
 
 
 
Total No. of patients (n)  30 
Age (years)  Mean±SD  44.83 ± 13.27 
Sex -  female:male  19:11 
Phenotype of disease Mucocutaneous (n)  30 
History of scalp involvement (n)  30 
Duration of disease (months)  Mean±SD  45 ± 16.87 
Duration of remission(months)  Mean±SD  32.512 ± 23.61 
DIF positive with either substrate  16 
No. of patients on treatment  17 
No of patients not on treatment  13 
No. of positive hair DIF  14 
No of positive skin DIF  10 
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Figure - 6 
 
 
 The age of patients in our study ranged from 17-69 years with a mean 
age of 44.34 years 
 
 Majority (33.3%) of the patients in our study were in the age group of 
41-50 years.  
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Figure - 7 
 
 Our study showed a female preponderance with a male-female ratio of 
1:1.7 
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Figure - 8 
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Figure - 9 
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Figure - 10 
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Figure - 11 
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Table – 5 
 
FREQUENCY OF HAIR AND SKIN DIF IN PEMPHIGUS 
PATIENT IN CLINICAL REMISSION 
 
Hair test 
Skin test P Value 
(Chi square test) Positive Negative 
Positive 
8 
57.1% 
6 
42.9% 
.010 
significant 
Negative 
2 
12.5% 
14 
87.5% 
 
 
 Of the total 30 patients, 16 patients had a positive DIF findings with 
atleast either one of the substrate. 
 The findings of hair skin DIF correlated with each other in 22 patients. 
 The sensitivity of hair DIF in our study was 80% 
 The specificity of Hair DIF was 70 %  
  There was a statistically significant association between skin and hair 
DIF findings with a p value of 0.010. 
 Positive Predictive value was 57.14%. 
 Negative Predictive value was 87.5%. 
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 Figure - 12 
 
 
 
 As seen above, hair DIF was positive in 14 patients whereas skin DIF 
was positive only in 10 patients 
 
 And Hair DIF was negative in 16 patients whereas skin was negative in 
20 patients. 
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Figure - 13 
 
 
 
 Of the 14 patients with positive hair DIF, 8 patients also had positive 
skin DIF. 
 
 
 However, in 6 patients hair DIF  was positive but skin was negative. 
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Table -  6 
 
ASSOCIATION BETWEEN HAIR DIF AND DURATION OF DISEASE 
 
DIF Of Hair N 
Duration of disease 
Mean±SD 
P Value 
Positive 14 41.57±30.09 .828 
Not significant Negative 16 48.00±35.18 
 
 
Table -  7 
 
SKIN DIF AND DURATION OF DISEASE 
 
 
 
 Patients with negative hair and skin DIF had a longer disease duration.   
 
 There was no statistically significant association between  mean disease 
duration and hair & skin DIF.  
 
 
 
DIF Of Skin N 
Duration of disease 
Mean±SD 
P Value 
Positive 10 38.70 ± 29.564 
. 680 
Not significant Negative 20 48.15 ± 34.176 
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Table -  8 
 
 
HAIR DIF AND DURATION OF REMISSION 
 
 
 
 
 
 Patients with positive hair DIF and a shorter duration of remission 
compared to patients with negative DIF. 
 
 However, the association between hair DIF and duration of remission 
was not statistically significant. 
 
 
 
 
DIF Of Hair N Duration of Remission Mean±SD 
P Value 
(independent T 
test) 
Positive 14 12.43±12.10 
0.072 
Not significant 
Negative 16 20.75±30.273 
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Table -  9 
 
SKIN DIF AND DURATION OF REMISSION 
 
 
 
 
 Patients with positive skin DIF and a shorter duration of remission 
compared to patients with negative DIF. 
 
 However, the association between skin DIF and duration of remission 
was not statistically significant. 
 
 
 
  
 
 
 
 
 
 
DIF Of SKIN N 
Duration of Remission 
Mean±SD 
P Value 
(independent T test) 
Positive 10 16.8±19.96 
0.931 
Negative 20 16.9± 25.735 
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Table – 10 
 
Hair DIF AND CURRENT TREATMENT 
 
 
 
 
 
 Hair DIF was positive in 50 %  patients and negative in 50 %  of 
patients who were currently not on treatment, 
 In Patients who were on treatment Hair DIF was positive in 44.4  %  and  
negative in 55.5 %. 
 Hence, in patients on treatment Hair DIF negativity was slightly higher. 
 However, the association between Hair DIF and current treatment was 
not statistically significant. 
 
 
Current treatment 
Hair dif 
P value 
(chi square test 
Positive Negative 
0.765 
NOT SIGNIFICANT 
Not on treatment 6 
50% 
6 
50% 
 
On treatment 8 
44.4% 
10 
55.5% 
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Table – 11 
 
 
SKIN DIF AND CURRENT TREATMENT 
 
 
 
 
 
 Skin DIF was positive in 41.6 % of patients and negative in 58.3 % of 
patients who were currently not on treatment, 
 In Patients who were on treatment Skin DIF was positive in 27.7 % 
patients and negative in 72.2 % patients.  
 Hence, in patients on treatment skin DIF negativity was slightly higher. 
 However the association between skin DIF and current treatment was 
not statistically significant. 
 
 
 
 
 
 
  
Current treatment SKIN DIF P Value 
(CHI SQUARE TEST 
Positive Negative 
0.429 
NOT SIGNIFICANT 
Not on treatment 5 
41.6% 
7 
58.3% 
On treatment 5 
27.7% 
13 
72.2% 
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Table – 12 
 
 
SKIN AND HAIR DIF FINDINGS IN PATIENTS NOT ON 
TREATMENT 
 
 
 
 
 Of the 30 patients, 12 patients were not on treatment. 
 
 Positivity with either substrate was seen in 7 patients. 
 
 And hair DIF was positive in 6 patients whereas skin DIF was positive 
only in 5 patients. But it was not statistically significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hair DIF 
SKIN DIF 
P Value 
(CHI SQUARE TEST 
Positive Negative 
0.0789 
NOT SIGNIFICANT 
Positive 4 2 
Negative 1 5 
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Table – 13 
 
 
ASSOCIATION BETWEEN DURATION OF REMISSION  AND 
GENDER 
 
 
 
 The Female patients had a longer duration of remission (20.16 
months)compared to the males(11.18 months) in our study. 
 And the association was found to be statistically significant with a p 
value of 0.05. 
 However, it should be emphasized that our study had a female 
predominance and the disease duration was also widely variable. 
 
 
Gender N 
Duration of Remission 
Mean±SD 
P Value 
(independent T test) 
Male 11 11.18 ±8.28 0.05 
Significant 
Female 19 20.16 ± 28.799 
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Table – 14 
 
ASSOCIATION BETWEEN HAIR DIF FINDINGS IN REMISSION 
AND GENDER 
 
 
 
 
 
 
 
 
 
 
Gender 
Hair DIF 
P Value 
(CHI SQUARE 
TEST 
Positive Negative 
0.156 
NOT 
SIGNIFICANT 
Male 7 
63.6% 
4 
36.4% 
Female 7 
36.8% 
 
12 
63.2% 
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Table – 15 
 
ASSOCIATION BETWEEN SKIN DIF FINDINGS IN REMISSION AND 
GENDER 
 
 
 
 There was no statistically significant association between gender and 
positivity of hair and skin DIF findings respectively, in remission.  
 
Gender 
SKIN  DIF 
P Value 
(CHI SQUARE TEST 
Positive Negative 
0.789 
NOT SIGNIFICANT 
Male 
4 
36.4% 
7 
63.6% 
Female 
6 
31.6% 
13 
68.4% 
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DISCUSSION 
 
 Pemphigus is a chronic autoimmune bullous disorder characterized by 
autoantibodies against desmogleins 3 and/ or 1.1 Steroids alone or with 
adjuvant immunosuppressives are the mainstay of treatment. The main goal of 
treatment is to maintain clinical remission with the least dosage of the 
immunosuppressives and eventually withdraw treatment when the patient has 
attained clinical and immunological remission. However, till date, there are no 
firm protocols devised for discontinuation of treatment. Various modalities 
currently available for assessment of immunological remission include anti-
desmoglein ELISA titres, direct immunofluorescence and indirect 
immunofluorescence.3-8 According to the British guidelines, treatment can be 
withdrawn primarily based on the clinical status of the patient, and 
immunofluorescence findings may aid the decision. 
 
 But , anti-desmoglein ELISA titres are expensive and not available in all 
clinical settings. And currently, IIF has much less value in assessment of 
disease activity as studies have shown that high dose steroids can cause rapid 
fall in the antibody titres and also, that they do not always correlate well with 
the disease activity.9-12 
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 David M et al in 1989, based on their study suggested that repeated 
negative DIF in pemphigus patients on clinical remission could be a sign of 
immunological remission.13 Similar findings were also reported by Balighi et 
al. and Ratnam et al.15,16 
 
 Ratnam et al, also noted that the patients with positive DIF findings 
during clinical remission had a significantly higher relapse rate after the 
discontinuation of treatment.16  
  
 Various studies have shown that the rate of relapse was about 44-100 % 
in patients with positive DIF findings during remission and 13-27% in patients 
with negative DIF.13,14 
 
 Wilson et al. in 1991, demonstrated that the human hair follicle is rich in 
the target antigens of pemphigus.134 Subsequently, Schaerer L, Trüeb RM in 
2003, first reported the positive DIF findings in the Outer root sheath of 
plucked hair in 100% of their patients and hence, suggested that hair DIF could 
be a suitable and non-invasive alternative to skin DIF.17 Similarly a study of 50 
patients with active pemphigus by Kumaresan, Rai R, et al in 2010,  also 
demonstrated 100% positivity of hair DIF.20 
 
 A study by Daneshpazhooh M et al. with 110 patients and Rao R et al. 
with 20 patients with active Pemphigus, showed positive DIF findings in 
90.9% and 85% of the patients, respectively.18,19 
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 Rao R et al in 2012, conducted a study to assess the role of hair DIF in 
monitoring the disease activity in pemphigus, they suggested that, in patients in 
clinical remission, DIF of hair could be an ideal substrate for assessment of 
immunological remission as it is simple and non- invasive.169 
 
 However, till date, there are only limited studies available, assessing the 
role of hair DIF in pemphigus patients in clinical remission. 
 
 With this background we conducted a study in our department with 30 
patients with Pemphigus Vulgaris, in clinical remission for atleast 6 months. 
All the patients in our study belonged to the mucocutaneous phenotype of 
Pemphigus and had a history of scalp involvement. The DIF of hair and skin 
was performed when the patient was at or more than 6 months of clinical 
remission.  
 
 The skin sample for our study was obtained from the upper trunk as a 
study showed that following oral mucosa, scalp and face the upper trunk is also 
rich in the target antigens of pemphigus. 
 In majority (30%) of our patients, the age of onset was between 31-40 
years, similar to other Indian studies.37,40,47 However, western studies 
have reported the common age of onset as 50-60 years.48 
 A study by Mascarenhas MF et al in Goa and Kanwar et al in North 
India showed a female preponderance.37,38 
Similarly, our study also showed a female preponderance with a male-                   
female ratio of 1:1.7 
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 In our study, 100% of our patients had positive DIF findings during the 
active stage of the disease, similar to the study by Schaerer & Trueb and 
Kumaresan, Rai R et al.17,20 
 
 To our knowledge,  apart from the study published by Rao et al. 
assessing the role of hair DIF in monitoring disease activity in pemphigus, 
there is only one study by Daneshpazhooh M et al. with 55 pemphigus patients 
in clinical remission for assessing the role of hair DIF in pemphigus patients in 
clinical Remission.170 
 
 In their study, the mean duration of disease was 69 months, whereas, in 
our study it was only 45 months. 
 In their study, the duration of remission was 12-24 months in majority 
of their patients(32/55), whereas, in our study majority(24/30) of the  
patients were in clinical remission only for a period of 6-12 months, 
which was significantly lower. 
 The sensitivity of hair DIF in their study was 79%, which is similar to 
our study with a sensitivity of 80 %. 
 The specificity of hair DIF  in their study was 48 % and in our study it 
was 70 %, which was significantly higher.  
 The positive predictive value of hair DIF in their study was 61% and in 
our study it was 57.14 %. The positive predictive value refers to the 
probability that the patients with positive results, truly have the disease. 
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 The negative predictive value of hair DIF in their study was 68 % 
whereas in our it was 87.5%, which was significantly higher.  
Negative predictive value is the probability that patients with a negative 
results, truly don't have the disease.  
 
 In our study, a total of 18 patients were on treatment. In these patients, 
the hair and skin DIF negativity was higher. In the remaining 12 patients, who 
were not on treatment, the positivity of hair DIF was higher than skin DIF. 
However, both the findings were not statistically significant. 
 
 In our study, 14 patients with negative skin and hair DIF, had a longer 
duration of disease and 8 patients with positive skin and hair DIF, had a shorter 
duration of remission. These findings were not statistically significant.  
 
 Interestingly, in our study we noted that the female patients had a longer 
duration of remission when compared to the males, which was statistically 
significant. However, it should be emphasized that our study had a female 
predominance and also the duration of disease among patients was widely 
variable. 
 
 We also noted that 50% of patients treated with steroids and 
azathioprine had both skin and hair DIF negative, whereas only 33% of patients 
treated with steroids and cyclophosphamide had both skin and hair DIF 
negative.  
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 Even though skin or mucosal DIF is considered as the ideal substrate for 
assessment of immunological remission, we would like to highlight the fact 
that 6 patients in our study  had  positive hair DIF even though skin DIF was 
negative. Thus, indicating that these patients were not yet in immunological 
remission. Had the clinician relied only on the DIF of skin for the assessment 
of the immunological status to aid his decision, this finding could have been 
missed and the patient’s treatment would have been discontinued prematurely.   
Hence, we suggest that DIF of hair can be done in patients with negative skin 
DIF, before declaring that the patient is in clinical and immunological 
remission and stopping the treatment. Alternatively, in patients in clinical 
remission, DIF of hair can be done at frequent intervals and when it becomes 
negative, DIF of skin could be done for confirmation and then the treatment 
can be discontinued. 
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CONCLUSION 
 
 
  Our study was done to assess the role of hair DIF in assessment of 
immunological remission in pemphigus . The sensitivity of hair DIF in our 
study was not high enough to suggest that it could replace the use of skin or 
mucosal DIF for assessment of immunological remission. However, one cannot 
disregard the positivity of hair DIF in the setting of skin DIF being negative as 
shown in our study. Hence, DIF of hair is a simple, non invasive & cost 
effective procedure and can be used as an additional procedure for assessment 
of immunological remission in Pemphigus Vulgaris. 
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PROFOMA 
 
• Name:                                    Gender: 
•  Age:                                        Occupation:  
 
•  Address and telephone number:  
•  Complaints with duration of illness: 
•  Date of starting treatment:  
•   Phenotype of Pemphigus: 
•  Sites of involvement:  
• History of scalp involvement:  
• Duration of clinical remission (absence of new, old, 
 or nonhealing lesion) :      
• Past treatment:  
• Stopped  treatment since:  
• Current treatment: 
• Duration of treatment: 
Study Volunteer ID:                                                   
Study Volunteer Name:  
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PSG Institute of Medical Science and Research, Coimbatore 
 
INFORMED CONSENT 
 
 
I , MANU VIDHYA. H ,  am  carrying out a study on the topic: COMPARISON 
OF DIF OF SKIN AND PLUCKED HAIR FOR EVALUATION OF 
IMMUNOLOGICAL REMISSION IN PEMPHIGUS as part of my research 
project being carried out under the aegis of the Department of: DERMATOLOGY 
VENEROLOGY & LEPROLOGY   
 
 My  research guide is: Dr. REENA RAI  
 
The justification for this study is:  
• Pemphigus is a group of autoimmune blistering disease of the skin and 
mucosa, characterized by relapses and remission. Systemic steroids alone or 
in combination with other immunosuppressive drugs are the main stay of 
treatment. Therefore, a system is required to monitor disease activity  so as 
to lower the dosage of the drugs and eventually withdraw treatment. Hence, 
DIF of skin and hair is being done to assess the immunological remission. 
 
 
 
The objectives of this study are:  
 
Primary Objective:  Comparison of DIF of skin and plucked hair for evaluation of 
immunological remission in pemphigus 
 
 
Secondary Objective:  To assess the senstivity and specificity of hair DIF for 
assessment of immunological remission in pempigus  
 
Sample size: 30  
 
Study  participants: Patients with pemphigus both biopsy and DIF proven 
 
Location:  PSGIMS & R 
We request you to kindly cooperate with us in this study. We propose to  collect 
background information and other relevant details related to this study. We will be 
carrying out:  
Study Volunteer ID:                                                   
Study Volunteer Name:  
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Initial interview (specify approximate duration): 15  minutes.  
 
Data collected will be stored for a period of  10 years. We will not use the data as 
part of another study. 
 
Clinical examination will be done to assess if any active  lesions are present  in 
the body. 
 
Procedure : 
Skin biopsy is a procedure that involves removing a piece of skin measuring 3-
5mm using an instrument. The area will first be anaesthtised by injecting a 
medicine called xylocaine.at the completion of the procedure a small dry sterile 
dressing will be applied and kept in place for 24hours. You will be given 
instructions regarding the care of biopsy site by the PI. 
Hair sample will be collected by plucking the hair from the scalp 
 
Benefits from this study:   
To assess the disease activity 
To stop medication based on the DIF reports. 
Based on the results of this study ,  to perfom only hair DIF & to avoid invasive 
skin biopsy procedure for assessment of immunological remission. 
 
Risks involved by participating in this study include: 
Infection, bleeding, scarring or pigmentation at the site of biopsy 
Risk of allergic reaction to the local anaesthetic. 
 
How the results will be used:  
Based on these results DIF of hair alone can be done as it is non invasive and 
simple procedure for monitoring of the disease activity. And skin biopsy which is 
an invasive procedure can be avoided. 
 
If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw from 
the interview / study at anytime. You have the freedom to withdraw from the 
study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a 
patient. You will NOT be paid any remuneration for the time you spend with us 
for this interview / study. The information provided by you will be kept in strict 
Study Volunteer ID:                                                   
Study Volunteer Name:  
Page 3 of 3 
 
confidence. Under no circumstances shall we reveal the identity of the respondent 
or their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any significant new 
findings - including adverse events, if any, – whether directly related to you or to 
other participants of this study, developed during the course of this research which 
may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to 
me, and has been explained to me by the investigator. Having understood the same, 
I hereby give my consent to them to interview me. I am affixing my signature / left 
thumb impression to indicate my consent and willingness to participate in this 
study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the PI  with date:      Witness: 
 
Contact number of PI: 9962559955 
 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
 
ABBREVIATIONS 
 
PV -  Pemphigus Vulgaris 
PF -  Pemphigus Foliaceous 
Dsg -  Desmogleins 
ORS -  Outer Root Sheath 
IRS -  Inner root sheath 
DIF -  Direct Immunofluorescence 
IIF -  Indirect Immunofluorescence 
FITC -  Fluorescent isothiocyanate  
CS -  Corticosteroids 
DCP -  Dexamethasone Cyclophosphamide pulse therapy 
CYP -  Cyclophosphamide 
BAD -  British Association Dermatologist. 
TPMT -  Thio-purine Methytransferase 
DVT -  Deep vein thrombosis 
BSA -  Body surface area 
H&E -  Hematoxylin and Eosin  
MMF -  Mycophenolate mofetil 
IVIg -  Intravenous immunoglobulin 
SLE -  Systemic Lupus Erythematosus 
AZN -  Azathioprine 
EBV  -  Ebstein Barr Virus 
HHV  -  Human Herpes Virus 
PRED - Prednisolone   
Methylpred –Methylprednisolone 
‘+’ - Positive 
‘-‘ - Negative 
 
Xg;gjy; gotk; 
 
njjp          
 
kDtpj;ah Q.;;;  Mfpa ehd;  PSG kUj;Jtf;fy;Y}hpapd; njhy; ghy;tpid ; ;; ;; ; kw;Wk; ; ;; ;; ;
bjhGneha;;;;  Jiwapd; fPH;  “Ko kw;;;;Wk; njhypy; cs;s  vjph; mq; ; ; ;; ; ; ;; ; ; ; tpdhy; ;;;
cz;lhff;Toa  bfhg;gs nehapd; ; ; ; ;; ; ; ;; ; ; ; bray;ghL  jd;ikia; ;; ;; ;  fz;lwpa[k; o.I.vg; vd;Dk; ; [ ; ; ; ;; [ ; ; ; ;; [ ; ; ; ;
kUj;Jt ghpnrhjid ;;; gw;wpa ;;; Ma;t;;; [[ [[” vd;w  jiyg;gpy; Ma;t[ nkw;bfhs;s cs;nsd; 
 
vd; Ma;t[ tHpfhl;o; ; [ ;; ; [ ;; ; [ ;  :   kU. hPdhuha; 
Ma;t[ nkw;bfhs;tjw;fhd mog;gil; [ ; ; ; ;; [ ; ; ; ;; [ ; ; ; ;  
 
njhypy; bfhg;gs neha; cz;lhtjw;F ekJ clypy; cs;s vjph;g;g[ rf;jp njhypy; 
,aw;ifahf cs;s  gir  nghd;w xU bghUSf;F vjph; mqit gy;ntW 
fhuz';fshy; cUthf;FfpwJ.  ,e;j gir nghd;w bghUspy; bray;jpwd; Fiwa[k; 
bghGJ xU bry; kw;bwhU bry;ypypUe;J gphpfpwJ.  ,Jnt bfhg;gs';fshf 
btspg;gLfpwJ.  ,e;j vjph; mqf;fis Fiwg;gjw;F kUe;Jfs; tH';fg;gLk;.  Mdhy; 
vd;W kUe;ij epWj;jntz;Lk; vd;gij jPh;khdpf;f njhy; kw;Wk; Koapy; cs;s 
nth;fspy; vjph;g;g[ mq cs;sjh vd;gij ghpnrhjpf;f 6 khj';fSf;F xU Kiw 
njhy; kw;Wk; Koia  o.I. vg;. vd;w ghpnrhjidia nkw; bfhs;s ntz;Lk;.  ,jid 
itj;J nehapd; bray;ghL  jd;ikia fz;lwpa ,aYk;.   
 
Ma;tpd; nehf;fk;; ; ; ;; ; ; ;; ; ; ;  
 nkw;Twpa ghpnrhjidia itj;J nehapd; bray;ghL jd;ikia 
Fiwe;Js;sjh mjpkhfpa[s;sjh vd;gij  fz;lwpe;Jbfhs;tnj ,e;j Ma;tpd; 
nehf;fk;/ mjw;F jf;fthW kUe;Jfs; bjhlh;e;J tH';fg;gl ntz;Lkh my;yJ 
epWj;jpf; bfhs;syhkh vd;gJ jPh;khdpf;fg;gLk;. 
 
Ma;tpy; g';F bgWk; egh;fspd; vz;zpf;if; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;; ; ; ; ; ; ; ;   :   30 egh;fs; 
Ma;t[ nkw;bfhs;Sk; ,lk; [ ; ; ;; [ ; ; ;; [ ; ; ; ; :   gp.v!;.$p kUj;Jtkid/  
njhy; ghy;tpid kw;Wk; bjhGneha; Jiw 
          
Ma;tpd; gyd;fs; ; ; ; ;; ; ; ;; ; ; ; : 
  nehapd; bray;ghL  jd;ikia fz;lwpag;gLk;.  
giHa epiyf;F jpUk;g[tij mwpe;J bfhs;sKoa[k;.   
 
 
Ma;tpdhy; Vw;gLk; mbrsfhpa';fs; ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ; / gf;f tpis;;; t[fs;; [ ;;[ ;;[ ;; : 
 
 nehahspfSf;F rij vLf;Fk;bghGJ rpyUf;F cjpug;nghf;F Vw;glyhk;.  
mJt[k; xU ijay; \yk; (njitg;gl;lhy;) rhp bra;ayhk;.  fpUkpfs; bjhw;Wk; mghak; 
kpft[k; Fiwe;j mstpy; cs;sJ.  v';fsJ fpUkp ehrp bray; \yk; ,Jt[k; 
jtph;f;fg;gLk;.   
 ,e;j Ma;tpy; fpilf;Fk; jfty;fs;  10 tUl';fs; ghJfhf;fg;gLk;.  ,it ntW 
ve;j Ma;tpw;Fk; gad;gLj;jg;gl khl;lhJ.  ve;j epiyapYk; c';fisg; gw;wpa 
jfty;fs; ahUf;Fk; bjhptpf;fg;gl khl;lhJ.  ,it ,ufrpakhf itf;fg;gLk;. 
,e;j Ma;tpy; g';nfw;f xg;g[f; bfhs;Stjhy; ve;jtpjkhd gyDk; c';fSf;F 
fpilf;fhJ.  ve;j neuj;jpy; ntz;LkhdhYk; Ma;tpypUe;J tpyfpf; bfhs;Sk; 
chpik c';fSf;F cz;L. 
Ma;tpypUe;J tpyfpf; bfhs;tjhy; c';fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j 
tpj khw;wKk; ,Uf;fhJ. 
,e;j Muha;r;rpf;fhf c';fsplk; rpy nfs;tpfs; nfl;fg;gLk; / rpy ,uj;j 
khjphpfs; my;yJ jpR khjphpfs; vLf;fg;gLk;. 
nkYk; ,e;j Ma;tpy; g';F bfhs;tJ c';fs; brhe;j tpUg;gk;.  ,jpy; ve;j  
tpjf; fl;lhaKk; ,y;iy.  eP';fs; tpUg;gg;gl;lhy; ,e;j Ma;tpd; Kot[fs; 
c';fSf;Fj; bjhpag; gLj;jg;gLk;. 
 
Ma;thshpd; ifbahg;gk; : 
njjp  : 
 
Ma;t[f;Fl;g; [ ; ;; [ ; ;; [ ; ; Lgthpd; xg;g[jy;; ; [ ;; ; [ ;; ; [ ; 
ehd; ,e;j Muha;r;rpapd; nehf;fk; kw;Wk; mjd; gad; ghl;oidg; gw;wp 
bjspthft[k; tpsf;fkhft[k; bjhpag;gLj;jg;gl;Ls;nsd;.  ,e;j Muha;r;rpay; g';F 
bfhs;st[k; ,e;j Muha;r;rpapd; kUj;Jt hPjpahd Fwpg;g[fis tUk; fhyj;jpYk; 
cgnahfg;gLj;jpf; bfhs;st[k; KG kdJld; rk;kjpf;fpnwd;. 
 
Ma;t[f;Fl;gLgthpd; bgah;/ Kfthp : : 
    ifbahg;gk;  : 
     njjp  : 
 kdpj bewpKiwf; FG mYtyfj;jpd; bjhiyngrp vz;. 0422-2570170  Extn. 5818 
